

## Review Article

# The role of microRNAs in pregnancies complicated by maternal diabetes

Manon D. Owen<sup>1</sup>, Margeurite G. Kennedy<sup>1,2,3</sup>, Rachel C. Quilang<sup>1,4</sup>, Eleanor M. Scott<sup>5</sup> and  Karen Forbes<sup>1</sup>

<sup>1</sup>Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, U.K.; <sup>2</sup>Anthony Nolan Research Institute, Royal Free Hospital, Hampstead, London, U.K.; <sup>3</sup>UCL Cancer Institute, Royal Free Campus, London, U.K.; <sup>4</sup>Department of Immunology, Leiden University Medical Center, Leiden, Netherlands; <sup>5</sup>Division of Clinical and Population Sciences, Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, U.K.

**Correspondence:** Karen Forbes (K.A.Forbes@leeds.ac.uk)



With the global prevalence of diabetes increasing, more people of reproductive age are experiencing hyperglycaemic pregnancies. Maternal Type 1 (T1DM) or Type 2 (T2DM) diabetes mellitus, and gestational diabetes mellitus (GDM) are associated with maternal cardiovascular and metabolic complications. Pregnancies complicated by maternal diabetes also increase the risk of short- and long-term health complications for the offspring, including altered fetal growth and the onset of T2DM and cardiometabolic diseases throughout life. Despite advanced methods for improving maternal glucose control, the prevalence of adverse maternal and offspring outcomes associated with maternal diabetes remains high. The placenta is a key organ at the maternal–fetal interface that regulates fetal growth and development. In pregnancies complicated by maternal diabetes, altered placental development and function has been linked to adverse outcomes in both mother and fetus. Emerging evidence suggests that microRNAs (miRNAs) are key molecules involved in mediating these changes. In this review, we describe the role of miRNAs in normal pregnancy and discuss how miRNA dysregulation in the placenta and maternal circulation is associated with sub-optimal placental development and pregnancy outcomes in individuals with maternal diabetes. We also discuss evidence demonstrating that miRNA dysregulation may affect the long-term health of mothers and their offspring. As such, miRNAs are potential candidates as biomarkers and therapeutic targets in diabetic pregnancies at risk of adverse outcomes.

## Introduction

With maternal diabetes currently affecting 21.1 million live births worldwide and the global prevalence of diabetes estimated to surge in the next 20 years [1], the influence of diabetes and associated hyperglycaemia on maternal health and the developing fetus is of increasing concern. Of the pregnancies affected by maternal hyperglycaemia, 19.7% are attributed to pre-existing maternal diabetes (PGDM), including Type 1 diabetes mellitus (T1DM) or Type 2 diabetes mellitus (T2DM), with gestational diabetes mellitus (GDM) being responsible for the remaining 80.3% cases [1]. Pregnancies complicated by PGDM and GDM are associated with short- and long-term adverse outcomes for both mother and offspring. Indeed, maternal hyperglycaemia accelerates the development of various comorbidities associated with diabetes, including diabetic retinopathy and cardiovascular disease [2,3]. These comorbidities are more common in individuals with PGDM compared with GDM, although they can occur in both [4,5]. Moreover, it is known that a diagnosis of GDM during pregnancy increases the risk of post-partum maternal T2DM onset by 7-fold [6]. People with PGDM or GDM have also been identified as a high-risk group for the development of preeclampsia [7,8] a disorder that poses risks to the growing fetus through its constraints on the oxygen supply to the placenta, as well as causing systemic inflammatory stress to maternal organs

Received: 15 April 2024  
 Revised: 14 August 2024  
 Accepted: 05 September 2024

Version of Record published:  
 18 September 2024

[9]. Preeclampsia is also associated with an increased maternal risk of developing cardiovascular diseases such as heart disease, stroke and hypertension post-partum [9].

Maternal diabetes not only adversely affects maternal health but is also associated with altered fetal growth, where neonates are more likely to be classed as large-for-gestational-age (LGA) (weighing above the 90th percentile of what is expected for their gestational age) [10–13]. At the opposite end of the spectrum, pregnancies complicated by maternal diabetes are also more likely to produce newborns that are small-for-gestational-age (SGA) (weighing below the 10th percentile of what is expected for their gestational age) compared with healthy pregnancies and can occur as a consequence of fetal growth restriction [14–16]. The aberrant fetal development observed in pregnancies affected by PGDM and GDM can also manifest as congenital abnormalities unrelated to birthweight, for example, cardiovascular and neural tube developmental defects are common in newborns exposed to hyperglycaemia *in utero* [2,7,17]. Birth defects are established early in fetal development, during organogenesis, and therefore the timing of the onset of maternal hyperglycaemia has a major impact on organogenesis and the risk of congenital anomalies [18]. This is illustrated by the markedly increased risk of congenital malformations witnessed in cases of PGDM, and the moderately increased risk seen in cases of GDM, as compared with normal pregnancies [19]. These risk differences reflect the clinical distinction of PGDM and GDM, where PGDM manifests as poor glycaemic control prior to conception, compared with GDM, where glycaemic control deteriorates during gestation. Although the exact mechanism is unknown, it is suspected that the hyperglycaemic milieu increases the levels of oxidative stress and apoptotic processes during embryogenesis, thus contributing towards the development of birth anomalies [2,19]. Environmental stressors applied early in development can reprogramme the transcriptome of an individual through epigenetic regulation, thereby predisposing them to diseases in adulthood. Specifically, it has been found that SGA and LGA offspring are more likely to develop disorders such as T2DM, obesity, hypertension and coronary artery disease in adulthood [16,20–24]. Research into the long-term effects that maternal diabetes has on offspring health has now indicated a similar link to cardiometabolic diseases in adulthood [25–27]. It is theorised that reprogramming of the genome in response to *in utero* stressors, such as maternal hyperglycaemia, is carried out through epigenetic changes in the genome, which alter gene expression through chromatin structural modifications and changes in the expression levels of non-coding RNAs such as miRNAs [22]. These modifications likely allow the fetus to adjust to an unfavourable intrauterine environment but when these changes are ill-matched to the future post-natal environment, problems can arise [21]. At present, it is not possible to predict which pregnancies complicated by maternal diabetes will result in short- or long-term complications for the fetus, and there are no treatments for LGA or SGA except for early delivery, which in itself can cause complications for the baby [28].

Continuous glucose monitoring (CGM), insulin pumps, sensor-augmented pump therapy, closed-loop systems and metformin therapy have all been employed as contemporary treatment strategies to regulate maternal glucose levels and health outcomes in pregnancies complicated by maternal diabetes [29–32]. However, despite apparently well-managed maternal glucose levels, the prevalence of abnormal fetal growth remains high in pregnancies affected by PGDM and GDM, with LGA occurring in ~10% of treated GDM, ~25% of treated T2DM and >50% of treated T1DM pregnancies [33–38]. This suggests that in addition to glucose, other factors may play a role in altering fetal development in diabetic pregnancies.

The placenta is a key regulator of fetal development and is core to the developmental origins of health and disease (DOHaD) hypothesis, where it is premised that suboptimal *in utero* exposures are associated with disease onset later in life [39]. Not only does the placenta maintain an optimal *in utero* environment throughout gestation, but its development invokes direct consequential effects on fetal growth and disease predisposition. As such, understanding how the placenta responds to stressors associated with maternal diabetes may help elucidate the mechanisms that influence fetal programming and offspring health outcomes later in life [40].

## The feto-placental unit

The human placenta is a transient organ that performs essential immunological and endocrine functions which help maintain gestation. Being at the interface between maternal and fetal circulations, it functions to exchange oxygen, carbon dioxide, nutrients and water between the maternal-fetal bloodstreams [41]. Maternal-fetal nutrient transfer capacity of the placenta during gestation has a profound impact on fetal growth, where fetal size is predominantly positively correlated to placental size, function and levels of nutrient transfer [41].

To meet the growing metabolic demands of the fetus and thus allow optimal nutrient transport between the maternal and fetal circulations, placental development and function is closely regulated throughout gestation. Upon implantation, extravillous trophoblasts (EVTs) invade the underlying uterine wall to anchor the placenta and remodel

uterine spiral arteries, to enable the perfusion of the placenta with maternal blood [42]. Cytotrophoblasts also differentiate into the multinucleated syncytiotrophoblast which forms the continuous outermost layer of the chorionic villi, termed the syncytium. Throughout gestation, the syncytium expands by the continuous proliferation, differentiation and fusion of the underlying cytotrophoblast populations of the placenta, where material is continuously shed into the maternal circulation [42,43]. These processes are regulated by growth factors, including insulin-like growth factors (IGFs), intracellular signalling cascades, mitochondrial respiration and microRNAs (miRNAs) [44–48]. In parallel, vasculogenesis and angiogenesis occur in the villous core to ensure the development of the placental vascular networks; whilst the precise mechanisms responsible for this remain to be established, numerous growth factors including vascular endothelial growth factor (VEGF) are essential regulators [49].

In the term placenta, the syncytiotrophoblast layer, which is in direct contact with maternal blood in the intervillous space, can reach approximately 12 m<sup>2</sup>, enabling a large surface area for exchange of nutrients and gases [50]. Oxygen and nutrients flow through the microvillous membrane (MVM) of the syncytiotrophoblast into the villus core, which is made up of mesenchymal cells and fetal capillaries, where they enter the fetal bloodstream and are transported to the fetus via the umbilical vein [51,52]. Many macro- and micro-nutrients are transported across the placenta, including glucose, fatty acids, amino-acids and folate. GLUT proteins, otherwise known as glucose transporters, located at the MVM and basal plasma membrane (BM) of the syncytium [41], are key for transporting glucose from maternal to fetal circulations via facilitated diffusion [53]. Fatty acid transport proteins (FATPs) are located on the MVM and BM, along with fatty acid binding proteins (FABPs) in the syncytial cytoplasm, which facilitate fatty acid transport across the placental barrier [54,55]. Similarly, amino acid transport proteins such as sodium-coupled neutral amino acid transporters (SNATs), expressed by the syncytiotrophoblast, facilitate the active transport of small non-essential amino acids such as alanine, glycine and serine into the fetal bloodstream [52,54].

Sex differences are observed in the placenta during early gestation, which are then maintained at term and linked to sex-dependent distinctions in adult tissues [56]. Interestingly, it has been shown that males dedicate more resources for fetal growth rather than placental growth, thus making their placentae smaller than females [57]. This suggests that male placentae are more vulnerable to adverse maternal environmental stimuli during gestation [57]. Indeed, given the angioarchitecture of the placenta where it is in constant contact with the maternal circulation, the placenta is heavily susceptible to environmental stressors found in the maternal circulation during pregnancy, such as the diabetic milieu in pregnancies complicated by maternal diabetes [58]. It is thought that such contact with hyperglycaemia and inflammatory cytokines interfere with the normal development of the placenta, leading to altered placental morphology [59]. These alterations to the placenta in pregnancies complicated by maternal diabetes affect its ability to facilitate the transfer of nutrients to the growing fetus, potentially resulting in pathologies such as aberrant fetal growth disorders [59,60]. Furthermore, given that fetal heart development is closely interlinked to placental development [61], it is possible that the impact of maternal diabetes on rates of congenital heart defects and long-term cardiovascular health of the offspring are also attributed to alterations in the placenta.

## Placental development in pregnancies complicated by maternal diabetes

The increasing prevalence of maternal hyperglycaemia during pregnancy has given rise to extensive research on the effects of diabetes on placental development and fetal health. It is already established that altered fetal growth in pregnancies complicated by maternal diabetes is associated with altered placental development [62]. Generally, diabetic pregnancies present with alterations in placental villous maturity, angiogenesis and placental weight [62,63]. Not only does the placenta adapt histologically and molecularly with PGDM and GDM, but these morphological changes also contribute towards altered uteroplacental blood flow which in turn impact fetal nutrient and oxygen supply. Indeed, uteroplacental flow adaptations have been associated with altered fetal growth, and T1DM, T2DM and GDM pregnancies all demonstrate placental hallmarks which contribute towards fetoplacental malperfusion [64–71]. To date, most studies reporting the impact of maternal diabetes on the placenta have focussed on GDM. However, even in the limited studies available for T1DM and T2DM pregnancies, it is clear that different types of diabetes exert distinct phenotypic differences on the placenta. As such, it is also important to consider the effect of both GDM and PGDM on placental development.

### Gestational diabetes mellitus

GDM is defined as maternal glucose intolerance that is first identified during pregnancy and is typically diagnosed through an oral glucose tolerance test (OGTT) at weeks 24–28 gestation [72,73]. The diagnostic criteria and degree of

hyperglycaemia in individuals with GDM can vary widely, resulting in broad clinical manifestations of GDM. Pancreatic  $\beta$ -cell dysfunction and insulin resistance are features of GDM and in some cases, it is thought that these hallmarks may already be underlying prior to conception, and are exacerbated during the maternal metabolic adaptations that occur in pregnancy [73]. Interestingly, it has been reported that the risk and severity of GDM is increased in pregnancies carrying a male fetus, where maternal blood glucose levels at OGTT are increased and  $\beta$ -cell function is reduced [74]. Controversy remains as to whether perinatal outcomes are less favourable for male or female offspring from pregnancies complicated by GDM [75–78]. Lifestyle interventions such as exercise and diet modifications are the main treatment for GDM. However, metformin and insulin are also used if maternal glycaemic levels do not improve. Glibenclamide is used rarely [73].

In contrast with uncomplicated pregnancies, GDM manifests with placental histological adaptations such as villous immaturity, villous oedema, decidual vasculopathy, chorangiosis, fibromuscular sclerosis, villous agglutination, retroplacental hemorrhage, altered fibrinoid necrosis, increased volume of intervillous space, terminal villous volume and surface area, as well as increased syncytiotrophoblast turnover and knotting [79–83]. These changes, along with altered placental amino acid and lipid transport result in aberrant feto-placental nutrient transfer [79]. Altered DNA methylation patterns and differentially expressed genes associated with cell death and activation, immune response and organ development have also been characterised in the placentae of those with GDM compared with uncomplicated pregnancies [84–86]. Other hallmarks of GDM placentae include altered oxidative stress and autophagy, mitochondrial dysfunction, placental macrophage (Hofbauer cell) accumulation and increased expression of inflammatory factors [87–93].

GDM is associated with a state of chronic low-grade placental inflammation, where proinflammatory cytokine expression is demonstrated to be sex-dependent [94]. Indeed, immune related pathways are shown to be altered in the placenta of male pregnancies complicated by GDM, further suggesting that the effect of the maternal diabetic milieu on placental immune pathways may be sex-specific [95]. GDM and offspring sex have also been identified to impact placental mitochondrial biogenesis, which could potentially result in male offspring being at increased risk of developing metabolic diseases during adulthood compared with females [96]. A sexually dimorphic effect has also been reported in placental amino acid metabolism in GDM pregnancies. As altered amino acid metabolism is associated with preeclampsia, intrauterine growth restriction and altered fetal brain development, this suggests that male and female offspring have a varied predisposition to gestational complications in GDM pregnancies [95]. A similar sex-specific effect has been identified in placental protein glycosylation in GDM, in that male placental O-GlcNAc transferase (OGT) expression is reduced compared with females, which may impact placental hormonal production [97].

## Type 1 diabetes mellitus

T1DM is characterised by pancreatic  $\beta$ -cell destruction, resulting in insulin insufficiency and hyperglycaemia. For most people, this pancreatic destruction is driven by autoimmunity. Insulin therapy is the main treatment for T1DM, including contemporary strategies such as CGM, insulin pumps and closed-loop systems. Although often diagnosed during childhood or adolescence, T1DM can also manifest later in life [98].

Various studies have demonstrated that T1DM pregnancies present with unique placental hallmarks associated with altered vascularisation which have not been reported in the placentae of those with GDM. These alterations include increased vascular leakiness, and increased capillary diameter, branching and capillary wall elongation, resulting in a higher villous volume and surface area [58,99,100]. Accelerated villous maturation is also more prominent in T1DM placentae compared with GDM [101]. Interestingly, placental GLUT-1 protein expression is also higher in T1DM pregnancies compared with GDM and has been positively correlated to fetal weight [102], suggesting altered glucose transfer. Although placentae of T1DM do not manifest as many lipid modifications as GDM, placental glycosylation and acylation pathways are more pronounced [103]. In contrast with GDM, people with T1DM manifest hyperglycaemia prior to conception and during early pregnancy. As such, these findings suggest that glucose and lipid metabolism, as well as glycosylation and acylation pathways in the placenta may be more sensitive to diabetic stimuli during early gestation rather than later in pregnancy. This may also be the case for placental vascularisation and villous maturation, where individuals with GDM do not present with these placental morphologies. Although it is not fully established whether these hallmarks are altered during early pregnancy/first trimester placenta of people with T1DM, it has been demonstrated that hyperglycaemia reduces first-trimester trophoblast turnover in T1DM placentae [104]. Further studies are needed to elucidate the broader effects of the T1DM diabetic milieu on the placenta in early pregnancy.



It is thought that the duration of T1DM may also be associated with adverse outcomes. Indeed, impaired placental extracellular matrix remodelling is a feature of T1DM pregnancies which has been shown to be augmented in longer-term T1DM mouse models [105–107]. Another feature of T1DM pregnancies is altered placental cellular stress [108]. Markedly reduced placental aerobic respiration activity and up-regulated hydrogen peroxide levels are observed in individuals with T1DM compared with BMI-matched normoglycaemic people [109]. However, T1DM placentae illustrate protective mechanisms against oxidative stress compared with GDM, where there is increased glutathione peroxidase activity, higher abundance of reduced glutathione and lower levels of oxidised glutathione [110]. Perhaps these protective mechanisms in T1DM may be as a consequence of longer-term adaptations to the diabetic milieu from conception, compared with those with GDM who are exposed to a diabetic environment for a shorter duration later in pregnancy and thus have a brief time-frame to develop protective adaptations in the placenta. This interpretation may also explain why placental infarcts were observed to be less abundant in T1DM pregnancies compared with GDM [64]. However, T2DM pregnancies also manifest with maternal hyperglycaemia as early as conception and interestingly, more infarcts were observed in the placentae of people with T2DM than T1DM [111]. It is possible that this finding may reflect study design, where pregnancy loss was not captured and only surviving pregnancies with fewer abnormalities were included in the study. T1DM is associated with more extreme first-trimester hyperglycaemia, congenital abnormalities and pregnancy loss than T2DM, and therefore perhaps this led to the collection of healthier placental samples of T1DM pregnancies compared with T2DM [111].

Another placental feature of T1DM pregnancies is heightened baseline vascular tone. It is thought that this may be a result of increased nitric oxide (NO) pathway activity in diabetes, unrelated to insulin levels [112]. Altered uterine NO-mediated vasodilation has been demonstrated in pregnant mice with GDM, where augmented superoxide levels may promote increased NO scavenging [113,114]. Aberrant adenosine-stimulated vasocontractility has also been identified in the fetoplacental vasculature of GDM and T1DM pregnancies [115]. However, further research is needed to investigate whether altered placental NO activity applies for GDM and T2DM pregnancies or is unique to T1DM. Moreover, systemic endothelial dysfunction has been associated with PGDM and GDM pregnancies [116,117].

Despite intensive strategies to achieve normoglycaemia in pregnant individuals with T1DM, these pregnancies still manifest distinct placental hallmarks contributing towards adverse fetal outcomes compared with GDM and healthy, uncomplicated pregnancies. As such, more studies are needed to explore the mechanisms contributing towards altered placental morphologies in T1DM pregnancies.

## Type 2 diabetes mellitus

Another form of PGDM is T2DM; a heterogeneous condition characterised by hyperglycaemia that is driven by insulin resistance and/or impaired pancreatic  $\beta$ -cell insulin secretion. This type of diabetes presents with varying underlying pathophysiology but is strongly associated with adiposity and a background of skeletal muscle, liver and adipose tissue insulin resistance [118]. Lifestyle interventions such as exercise, diet changes and weight loss are the main initial treatment strategy for T2DM. However, multiple oral hypoglycaemic agents and injectables such as insulin and glucagon-like peptide-1 (GLP-1) agonists are also commonly required [118,119]. Although traditionally, T2DM occurred with advancing age, it is increasingly being diagnosed in children and young adults; this is known as early onset T2DM (EOT2D). This is a concern as it is a more severe condition if diagnosed <40 years-of-age and associated with greater risk of complications. T2DM is now far more common than T1DM in women of child-bearing age [118–120].

T2DM pregnancies are characterised by up-regulated placental glucose, amino acid and fatty acid transporter expression compared with BMI-matched normoglycaemic pregnancies [121,122]. This highly suggests that fetoplacental nutrient transfer and metabolism are altered in T2DM. With T2DM being a heterogeneous condition that is predominantly associated with adiposity, it is possible that the altered placental nutrient transfer observed in these individuals may reflect maternal nutrient excess that is associated with T2DM pregnancies. As such, it is reasonable to assume that pathological placental development in individuals with T2DM may be driven by metabolic disturbances of various metabolic tissues rather than pancreatic dysfunction exclusively. Indeed, lipoperoxidation is another placental feature of T2DM pregnancies, as well as placental calcification which is mostly identified in T2DM compared with T1DM and GDM pregnancies [122,123]. These placental hallmarks have been associated with maternal adiposity in mice, where increased placental labyrinth lipid peroxidation and calcification have been identified in male offspring of obese dams [124]. Moreover, placental calcification has been identified as a predictor of suboptimal uteroplacental flow [125], and this is further evidenced by the increased prevalence of decidual vasculopathy in T2DM compared with GDM pregnancies [64].

Maternal obesity has also been demonstrated to influence placental labyrinth adaptations to cellular stress [124]. It is possible that this could be a response to the altered placental aerobic respiratory activity that is observed in people with T2DM [109]. Inflammation is another feature mostly associated with T2DM pregnancies compared with T1DM and GDM [123]. This hallmark is consistent with placental features of pregnancies complicated by maternal obesity, where it is suggested that increased inflammation may be a response to exacerbated cellular oxidative stress and altered metabolism [126].

Moreover, similarly to T1DM, accelerated placental villous maturation has also been identified in T2DM pregnancies [101,102]. Disorders of villous maturity are associated with fetal death [127] and it has been demonstrated that PGDM increases the risk of stillbirth, where obesity can amplify this risk [128]. These findings, along with the altered placental glucose metabolism identified exclusively in PGDM pregnancies [102,121], further suggest that placental glucose transport and villous maturation may be most susceptible to the maternal diabetic milieu at earlier stages of pregnancy. Additional studies on first trimester placental tissue are required to validate the effects of PGDM on adverse fetal outcomes compared with GDM pregnancies.

## Factors contributing towards placental pathology in diabetes

*In utero* hyperglycaemia is inherent to GDM, T1DM and T2DM pregnancies. However, each diabetes type demonstrates a distinct set of placental features. This is unsurprising given the variance in clinical manifestations and pathophysiological characteristics belonging to each type and thus suggests that factors other than glucose may contribute towards placental phenotypic adaptations in diabetes. This may include hypoglycaemic agents such as metformin, which has been demonstrated to alter placental development and function [29,129,130]. This is further supported by studies showing that individuals with well-managed glucose levels still manifest with pathological placental hallmarks [131–133]. These changes in the placenta could potentially be explained by the increasing evidence demonstrating that in addition to glycaemic control, fetal sex, maternal weight, ethnicity and the underlying pathophysiology and duration of the diabetes types can all contribute towards distinct pathological hallmarks [63,107]. There are limited studies investigating the possible mechanisms responsible for the impact of T1DM and T2DM on the placenta and fetus, however, clear evidence shows that miRNAs are key regulators of normal placental development and are mediating factors contributing towards placental pathology and associated adverse outcomes in pregnancies complicated by GDM ([134–138], Tables 1–3).

## miRNAs in pregnancy microRNA biogenesis

microRNAs are essential for most cellular and biological processes, including regulating placental development [134,139]. miRNAs are non-coding RNAs that are temporally expressed at different developmental timepoints. They modulate gene network expression post-transcriptionally, either by suppressing mRNA translation via signalling mRNA for degradation or deadenylation, or by stimulating gene expression via relief of repression [140–142]. With an average size of 22–23 bp, these single-stranded miRNAs are highly conserved structures which are produced from a tightly regulated process. First a hairpin loop structure, known as primary(pri)-miRNA is transcribed from genic or intergenic (known as mirtrons) regions in the nucleus. These pri-miRNA are then processed to 60–70 nucleotide-long precursor(pre)-miRNA and then 22–23 nucleotide mature miRNA molecules through a sequence of events involving the endonucleases, Drosha and Dicer. Following the processing of pre-miRNA, it was previously thought that one strand of the miRNA duplex was degraded, leaving only one functionally active mature strand. However, it has now become apparent that both strands of the miRNA duplex are functionally active. As such, this has coined the -3p and -5p nomenclatures used to describe miRNAs, in order to differentiate the mature miRNAs deriving from the 3' and 5' terminals of the pre-miRNA hairpin structure [143]. Mature, functionally active miRNA strands then bind the 3'-untranslated region (UTR), or in some instances, 5-UTR, of target mRNA to induce translational repression or mRNA degradation; reviewed in [139,141]. Multiple miRNAs work simultaneously to regulate broad gene networks, resulting in pleiotropic downstream effects in the cell or tissue in which they reside. Interestingly, many miRNAs are temporally synthesised in a tissue-specific manner, including the placenta whereby distinct expression profiles are found at different stages of gestation [134–136], suggesting that miRNAs may play specific roles in the placenta. Indeed, several studies have shown that miRNAs are key regulators of placental development and function [134].

## microRNAs in the placenta

Some of the most compelling evidence for a role of miRNAs in the placenta is evident from evolutionary studies. Recently, a group of 13 miRNA gene families have been shown to originate early in placental mammal evolution,

**Table 1** Altered placental miRNA regulation and their known targets and functional outcomes in pregnancies complicated by maternal diabetes

Diabetes type	miRNA regulation	Model	Target	Functional outcome	Reference
GDM	↓ miR-29b	Human placental tissue and HTR-8/Svneo cells	↑ HIF3A	↑ cell migration and invasion	[210]
GDM	↓ miR-143	Human placental tissue and primary syncytiotrophoblast	↓ PPAR $\gamma$ ↓ PGC1 $\alpha$ ↑ hPL ↑ GLUT1 ↑ mTOR	↓ mitochondrial respiration	[211]
GDM	↓ miR-21	Human placental tissue and HTR-8/Svneo cells	↑ PPAR $\alpha$	↓ cell growth and infiltration	[212]
GDM	↑ miR-518d	Human placental tissue and HEK-293T cells	↓ PPAR $\alpha$	Altered fatty acid and glucose metabolism	[213]
GDM	↑ miR-98	Human placental tissue, JEG-3 and HEK-293T cells	↓ MeCP2 ↓ TRPC3	↑ global DNA methylation ↓ insulin-mediated- uptake of glucose	[214]
GDM	↓ miR-138-5p	Human placental tissue and HTR-8/Svneo cells	↑ TBL1X	↑ cell proliferation and placental growth	[215]
GDM	↓ miR-9 ↓ miR-22	Human placental tissue, primary syncytiotrophoblast, HEK-293T and HTR-8/Svneo cells	↑ GLUT1 ↑ HK2	↑ glucose uptake, lactate secretion and cell viability ↓ apoptosis	[216]
GDM	↑ miR-140-3p	Human placental tissue and umbilical vein endothelial cells, HEK-293T and HTR-8/Svneo cells	↓ IR- $\alpha$ ↓ IGFR1	Defective insulin receptor signalling	[217]
GDM	↓ miR-132	Human placental tissue and BeWo and HTR-8/Svneo cells	PTEN	↓ cell proliferation	[218]
GDM	↓ miR-6795-5p	Human placental tissue, HEK-293T and HTR-8/Svneo cells	PTPN1	Altered insulin signalling, cell growth and glucose metabolism	[219]
GDM	↑ miR-136	Human placental tissue, BeWo and HTR-8/Svneo cells	↓ E2F1	↓ cell proliferation	[220]
GDM	↓ miR-345-3p	Human placental tissue, HEK-293T and HTR-8/Svneo cells	↑ BAK1	↑ apoptosis ↓ proliferation and migration	[221]
GDM	↑ miR-95 ↑ miR-548am ↓ miR-1246	Human placental tissue	↓ GLUT1 ↓ GLUT3 ↓ GLUT4	Aberrant insulin signalling pathway	[222]
GDM	↓ miR-22 ↓ miR-372	Human placental tissue and HTR-8/Svneo cells	↓ GLUT4	Aberrant insulin signalling pathway	[223]
GDM	↓ miR-30d-5p	Human placental tissue and HTR-8/Svneo cells	↑ RAB8A	↑ cell proliferation, migration, invasion and glucose uptake	[163]
GDM	↑ miR-1323	Human HTR-8/Svneo and BeWo cells	↓ TP53INP1	↓ cell viability	[224]
GDM	↑ miR-657	Human placental mononuclear macrophages and THP-1 cells	↓ FAM46C	↑ cell proliferation, migration and polarisation towards M1 phenotype	[225]
GDM	↑ miR-199a	Human placental tissue and JEG-3 cells	↓ MeCP2 ↓ TRPC3	Altered methylation patterns and glucose metabolism	[226]
GDM	miR-195-5p	Human pulmonary microvascular endothelial cells and mouse placental tissue	↓ VEGFA	↑ endothelial cell dysfunction	[227]
GDM	↓ miR-6869-5p	Human placental mononuclear macrophages and THP-1 cells	↑ PTPRO	↓ cell proliferation, inflammatory response ↑ polarisation towards M2 phenotype	[228]
GDM	↑ miR-101	Human umbilical vein endothelial cells	↓ EZH2	↓ gene transcription	[229]

Continued over

**Table 1 Altered placental miRNA regulation and their known targets and functional outcomes in pregnancies complicated by maternal diabetes (Continued)**

Diabetes type	miRNA regulation	Model	Target	Functional outcome	Reference
GDM	↑ miR-134-5p	HTR-8/Svneo and HEK-293T cells	↓ FOX P2	↑ inflammation and apoptosis	[230]
GDM	↑ miR-137	Human umbilical vein endothelial cells, U937 and THP-1 cells	↑ CCL2	↓ cell viability and angiogenesis ↑ inflammatory cytokine secretion, cell activation, monocyte chemotaxis and adhesion	[231]
GDM	↓ miR-9-5p	Human placental tissue and primary syncytiotrophoblast	↑ HK2 ↑ GLUT1 ↑ PFK ↑ LDH	Altered aerobic glycolysis and mitochondrial complex expression	[232]
GDM	↑ miR-195-5p	Human umbilical vein endothelial cells and HEK-293T cells	↓ EZH2	↓ cell proliferation and viability ↑ apoptosis	[233]
GDM	↓ miR-96-5p	Human placental tissue and HTR-8/Svneo cells	-	↓ cell viability	[234]
GDM	↓ miR-193b	HTR-8/Svneo cells	↑ IGFBP5	↑ autophagy and apoptosis	[235]
GDM	↑ miR-34b-3p	Human umbilical vein endothelial cells	↓ PDK1	↓ cell viability and migration	[236]
GDM	↑ miR-190b	Human placental tissue, Min6 cells and mouse β-cells	↓ NKX6-1	↓ cell activity, proliferation, islet insulin secretion	[237]
GDM	↑ miR-503	Human placental tissue, INS-1 and HEK-293T cells	↓ mTOR	Pancreatic β-cell dysfunction	[238]
GDM	↑ miR-144 ↓ miR-125b	Human placental tissue	-	Abnormal glucose metabolism	[239]
GDM	↓ miR-96	Human placental tissue, INS-1 and HEK-293T cells	↑ PAK1	↓ insulin secretion and β-cell function	[240]
GDM and T2DM	↓ miR148a-3p ↓ miR29a-3p	Human placental tissue and umbilical vein endothelial cells	AMPKα1 IGFR1 IRS1/2 PPARγ PI3K	Altered insulin signalling and glucose metabolism	[209]
T1DM	<i>No studies identified</i>				
T2DM	<i>No studies identified</i>				

Abbreviations: AMPK, adenosine monophosphate-activated protein kinase; BAK, BCL-2 homologous antagonist killer; CCL, C-C motif chemokine ligand; E2F1, E2F transcription factor 1; EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit; FAM46C, family with sequence similarity 46, member C; FOX P, forkhead box protein P; GALNT, polypeptide N-acetylgalactosyltransferase; GLUT, glucose transporter; HIF, hypoxia-inducible factor; HK, hexokinase; hPL, human placental lactogen; IGFBP, insulin-like growth factor-binding protein; IGFR, insulin-like growth factor; IR, insulin receptor; IRS, insulin receptor substrate; LDH, lactate dehydrogenase; MeCP, methyl CpG binding protein; mTOR, mammalian target of rapamycin; NKX6-1, NK6 homeobox 1; PAK, p21-activated kinase; PDK, pyruvate dehydrogenase kinase; PFK, phosphofructokinase; PGC, peroxisome proliferator-activated receptor-γ coactivator; PI3K, phosphoinositide 3-kinase; PPAR, peroxisome proliferator-activated receptor; PTEN, phosphatase and tensin homolog; PTPN, protein tyrosine phosphatases, non-receptor type; PTPRO, protein tyrosine phosphatase receptor type O; RAB8A, Ras-related protein Rab-8A; TBL1X, transducin β like 1 X-linked; TP53INP, tumour protein p53-inducible nuclear protein; TRPC, transient receptor potential channel; VEGF, vascular endothelial growth factor.

suggesting a key role in processes specific to placental mammals [137]. Whilst these miRNAs are expressed in many cells and tissues, evidence supporting this comes from a recent study showing that within the endometrium, some of these evolutionary conserved miRNAs have an important role in regulating the initial stages of implantation [144]. Given their expression in the human placenta, it is likely that these miRNAs also play key roles in the placenta. Other evidence for a strong link between the evolutionary conservation of miRNAs across various placental mammals comes from work demonstrating that some miRNA encoding genes arise from different evolutionary chromosomal clusters and are significantly or exclusively expressed in the placenta of various mammalian species [138].

The chromosome 19 miRNA cluster (C19MC) is a key maternally imprinted, primate specific, cluster found within the human placenta, where 46 genes encode 59 mature, placental-specific miRNAs [134,135,145,146]. The eutherian specific, paternally imprinted chromosome 14 miRNA cluster (C14MC) is another key cluster consisting of 52 miRNA genes which encodes 84 mature miRNAs that are mostly exclusively expressed in the placenta [147–150].



**Table 2** Altered maternal circulating miRNAs of placental origin and their known targets and functional outcomes in pregnancies complicated by maternal diabetes

Diabetes type	miRNA Regulation	Source	Target	Functional outcome	Reference
GDM	↑ miR-135a-5p	Maternal plasma EVs (including characterisation of placenta-derived EVs based on PLAP expression)	↑ SIRT1	↑ trophoblast proliferation, invasion and migration	[273]
GDM	↑ miR-130b-3p	Secreted EVs from cultured placental MSCs	↓ ICAM-1	↑ HUVEC proliferation, migration and angiogenesis	[274]
GDM	↓ miR-140-3p ↓ miR-574-3p	Secreted EVs from cultured placental villous explants	↓ VEGF	↑ cell proliferation, migration and tube formation	[275]
GDM	↑ miR-125a-3p ↑ miR-224-5p ↑ miR-584-5p ↑ miR-186-5p ↑ miR-22-3p ↑ miR-99b-5p ↑ miR-433-3p ↑ miR-197-3p ↑ miR423-3p ↓ miR-208a-3p ↓ miR-335-5p ↓ miR-451a ↓ miR-145-3p ↓ miR-369-3p ↓ miR-483-3p ↓ miR-203a-3b ↓ miR-574-3p ↓ miR-144-3p ↓ miR-6795-5p ↓ miR-550a-3-3p ↓ miR-411-5p ↓ miR-550a-3-3p ↓ miR-140-3p	Secreted EVs from cultured placental villous explants	–	↓ primary skeletal muscle cell insulin-stimulated migration and glucose uptake	[276]
GDM	↓ miR-516-5p ↓ miR-517-3p ↓ miR-518-5p ↓ miR-222-3p ↓ miR-16-5p	Maternal urine EVs (including characterisation of placenta-derived EVs based on PLAP expression)	IRS4 GALNT RECK ALG3 AKT3 TIMP3 KIT L2HGDH KI2FC RAP1 HOXC8 PD-L1	Altered insulin signalling, metabolic homeostasis and inflammatory response	[199]
GDM	↑ miR-520h ↑ miR-1323 ↑ miR-136-5p ↑ miR-342-3p	Maternal serum EVs (including characterisation of placenta-derived EVs based on PLAP expression)	↓ AMPK ↓ GLUT2	Altered β-cell insulin secretion, β-oxidation and glucose transport	[200]
T1DM	<i>No studies identified.</i>				
T2DM	<i>No studies identified.</i>				

Abbreviations: AKT, RAC-gamma serine/threonine-protein kinase; ALG3, asparagine-linked glycosylation protein 3 homolog; AMPK, adenosine monophosphate-activated protein kinase; GALNT, polypeptide N-acetylgalactosaminyltransferase; GLUT, glucose transporter; HOX, homeobox; HUVEC, human umbilical vein endothelial cell; ICAM, intracellular adhesion molecule; IRS, insulin receptor substrate; KI2FC, kinesin family member 2C; KIT, KIT proto-oncogene, receptor tyrosine kinase; L2HGDH, L-2-hydroxyglutarate dehydrogenase; MSC, mesenchymal stem cell; PD-L, programmed death-ligand; PLAP, placental alkaline phosphatase; RAP, Ras-related protein; RECK, reversion inducing cysteine rich protein with kazal motifs; SIRT, Sirtuin; TIMP3, tissue inhibitor of metalloproteinase-3; VEGF, vascular endothelial growth factor.

This cluster is divided into genomic regions known as the miR-127/miR-136 and miR-379/miR-410 clusters [151]. The marked or exclusive expression of these miRNA clusters within the placenta suggests that they have key functional relevance in this organ. Indeed, miRNAs originating from C19MC are the predominant miRNAs found in term human trophoblasts and are key in regulating trophoblastic mRNA and protein profiles to maintain cellular

**Table 3 miRNAs associated with altered fetal growth in pregnancies complicated by maternal diabetes**

Model	Source	miRNA regulation	Functional outcome/target	Fetal growth outcome	Reference
GDM	Human placental tissue	↑ miR-508-3p ↓ miR-27a ↓ miR-9 ↓ miR-137 ↓ miR-92a ↓ miR-33a ↓ miR-30d ↓ miR-362-5p ↓ miR-502-5p	EGFR signalling	Macrosomia	[283]
GDM/T2DM	Human maternal serum and placental tissue	↑ miR-16/↓ miR-16	CUL4A SMAD1 EGFR ACTB RRP12 DAB2	Macrosomia/SGA	[284,285]
GDM	Human maternal plasma and placental tissue	↓ miR-517a	↑ IGF-1 and trophoblast proliferation	Macrosomia	[286]
GDM and T2DM	Human placental tissue	↓ miR-126-3p	IRS1 PI3K	Lower birth weight	[209]

Abbreviations: ACTB,  $\beta$ -actin; CUL4A, Cullin 4A; DAB2, Disabled-2; EGFR, epidermal growth factor receptor; IGF-1, insulin-like growth factor 1; IRS1, insulin receptor substrate 1; PI3K, phosphatidylinositol 3-kinase; RRP12, ribosomal RNA processing 12 homolog; SMAD1, small body size and mothers against decapentaplegic family 1

homeostasis [145]. Placental targets of C19MC miRNAs have also been mapped to functions associated with DNA binding, protein phosphorylation, cytokine response, oxidative stress and regulation of growth and apoptosis [146]. The miR-371-3 cluster, located downstream to C19MC, is also primarily expressed in placental tissue and is involved in regulating cellular proliferation and apoptosis [152,153]. The role of C14MC miRNAs in pregnancy is yet to be fully established; however, the miR-127/miR-136 cluster has been shown to be involved in fetal capillary development and the miR-379/miR-410 cluster has been demonstrated to influence trophoblast proliferation and migration [147,151]. Another cluster involved in placental development is miR-17/92. This cluster is not placenta-specific but consists of six miRNAs (miR-17, miR-18a, miR-19a, miR-19b, miR-20a and miR-92a) which mediate key placental growth processes such as angiogenesis, trophoblast proliferation, spiral artery remodelling and cell cycle regulation [154,155]. Evidence also points towards miR-17/92 and its paralog cluster, miR-106a-363, playing a role in trophoblast differentiation through the regulation of estrogen receptor  $\alpha$  (ER $\alpha$ ) [156].

It has been established that the placental miRNA atlas is sexually dimorphic [157]. Whilst there is a clear evolutionarily conserved role for some placental miRNAs, more than 2000 mature miRNAs have been detected in the human placenta and the vast majority of these are highly conserved across different cells and tissues, likely due to their roles in key physiological or homeostatic processes. Indeed, the top four most abundant placental miRNAs (miR-30d-5p, miR-100-5p, miR-143-4p and miR-21-5p) play significant roles in tissues beyond the placenta [48,158–162]. miR-30d has been associated with cancer progression and cardiac hypertrophy [163,164]. miR-100-5p is known to regulate skeletal muscle myogenesis [165] and miR-143-3p has been demonstrated to regulate vascular smooth muscle differentiation and modify autophagy in endometrial stromal cells [166,167]. miR-21 is highly conserved and is almost ubiquitously expressed, where its abundance has been associated with HTR8/SVneo cell proliferation and pregnancies complicated by preeclampsia [168,169]. It has also been shown that miR-21 plays a key role in epithelial–mesenchymal transition [170]. There are other various regulatory miRNAs which are key for placental development [171], some of which include; let-7a and miR-145, which regulate trophoblast proliferation, and vascular development and cell turnover of other tissues [48,158–162]; miR-96-5p which regulates proliferation and migration of trophoblasts as well as in vascular smooth muscle cells [172,173]; miR-29a which regulates muscle and skeletal function and homeostasis, immune system modulation and haematopoiesis of various tissues [174,175]; and miR-125b which regulates trophoblast migration and invasion, as well as playing a role in mitochondrial biogenesis and adipocyte development and function [176,177]. Given the abundance of other miRNAs in the placenta and evidence that several are altered in pregnancy complications such as fetal growth restriction, other yet unreported roles for miRNAs is likely. Indeed miR-16, miR-21 and miR-199a are examples of this. These miRNAs are associated with fetal growth and whilst their functional roles in the placenta remain to be established, these miRNAs regulate insulin sensitivity and glucose

metabolism in other cells and tissues [178–183]. Exploring these roles in the placenta would further our understanding of the currently unreported roles of various miRNAs in pregnancy.

## Circulating microRNAs in pregnancy

In addition to considering the role of miRNAs that are detected in the placenta, the role of miRNAs in the circulation should also be considered. Indeed, sexually dimorphic patterns have been identified for maternal circulating miRNAs in pregnancies complicated by altered fetal growth [184]. Whilst miRNAs are transcribed and functionally active in their tissue of origin, they can be released into circulation encapsulated in extracellular vesicles (EVs). EVs are produced from all cells and tissues and can be subcategorised according to size, density, molecular composition or cellular origin into the following classes; small EVs (typically <200 nm in diameter) and large EVs (typically >200 nm in diameter) [185–187]. EVs contain DNA, miRNAs, mRNAs, proteins and lipids, with their cargo reflecting phenotypic hallmarks of their cell of origin [188,189]. As such, EVs and their cargo demonstrate potential as biomarkers for different pathological conditions. However, other ‘hormonal-like’ roles for EVs are also emerging. When released from cells, EVs can be transported into local and distal cells via a variety of mechanisms including clathrin-mediated endocytosis, membrane fusion, macropinocytosis and phagocytosis [190] and thus can influence the transcriptome of target cells via their miRNA cargo. As such, this EV-mediated transport in the human circulation allows systemic bidirectional interorgan cross-talk via miRNA regulation [188].

With regards to the placenta, its production of EVs has been long established, following the discovery that syncytiotrophoblast sheds microparticles (0.2–2 µm) that are capable of immunoregulation of circulating monocytes [191–193]. More recently, it has been reported that the concentration of EVs in the maternal circulation is increased in pregnancy, and that placental-derived EVs play a key role in regulating maternal glucose homeostasis [194–196]. Interestingly, EV-labelling techniques in *in vivo* murine models have shown that placental EVs can also interact with various maternal cells and tissues, including endothelial and immune cells, lung, kidney and liver [194]. This suggests that placenta-derived EVs may also have other important roles in regulating maternal homeostasis during pregnancy.


Whilst the specific EV cargo involved in these interactions have not been fully elucidated, several studies suggest that they are likely attributed to miRNAs. Indeed, the presence of trophoblast-specific C19MC and non-C19MC miRNAs in the maternal circulation during pregnancy has been reported [147,197,198] and placenta-derived EV-miRNA profiles have been shown to be altered with gestational age [199,200]. Functional roles for placental derived EV miRNAs have also been reported. EV-encompassed C19MC and miR-17-92 cluster miRNAs have been shown to play immunomodulatory roles during pregnancy by influencing events in maternal immune cells [145,201–203].

While the concept of feto-maternal signalling via EVs and their miRNA cargo is well regarded in the literature, evidence is also emerging for a role of EVs and their cargo in maternal–placental communication. Holder et al.’s [2016] visualisation of the internalisation of PKH labelled maternal macrophage-derived EVs by the placenta was one of the first to show that EV-mediated communication between maternal cells/tissues and the placenta is bidirectional [204]. The functional consequence of maternal–placental EV communication has also been established, where maternal macrophage EVs modulate placental cytokine production [204] and maternal adipose tissue EVs influence placental glucose metabolism by altering genes involved in glycolysis and gluconeogenesis [188]. Whilst the EV cargo responsible for exerting these maternal–placental effects of EVs has yet to be established, there are reports that miRNAs released from maternal organs can traffic into placental and fetal tissues to influence feto-placental development [188,197,205]. This suggests that the maternal metabolic state and environment may impact on placental function and fetal growth via EV-miRNAs. Recent work within our group also supports this hypothesis [184,206,207]. It is therefore possible that whilst many miRNAs are produced by the placenta, other mature miRNAs present in the placenta are a consequence of being transported to the placenta from maternal (or fetal) circulations, and that these may be altered in pathological conditions.

## microRNAs in pregnancies complicated by maternal diabetes

### Placental miRNAs

In pregnancies complicated by maternal diabetes, there is an altered placental miRNA profile compared with healthy pregnancy (Table 1). Whilst the mechanisms through which a diabetic environment alters placental miRNA levels remain to be elucidated, it is clear that miRNAs have an integral role in feto-placental development and that they may contribute to adverse outcomes in these pregnancies. miRNAs elicit functional changes in target expression through DNA methylation-associated mechanisms which represses messenger RNA transcription. In turn, miRNA-encoding genes and some miRNAs themselves may also be methylated to regulate miRNA expression [208]. It has been postulated that these methylation patterns may influence miRNA regulation in response to certain treatments. As such,



**Figure 1. Effect of maternal diabetes on placental miRNA profile and functional outcomes**

Pregnancies complicated by maternal diabetes are associated with a dysregulated placental miRNA and proteomic profile. As a result, studies have identified maternal diabetes leads to alterations in placental growth, insulin signalling and glucose uptake, epigenetic regulation, cell migration and invasion, vascular development, inflammation, autophagy and mitochondrial metabolism. Created using Biorender.com.

this shows that miRNAs have a significant role in multifaceted epigenetic events which may play important roles in health and disease functional outcomes [208].

Using various models, it has been established that miRNAs that have been identified to be altered by maternal diabetes in placental tissue have many overlapping targets; sharing functional hallmarks associated with placental growth, insulin signalling, glucose metabolism, inflammation and vascular development [163,209–240] (Table 1 and Figure 1). Indeed, among these dysregulated miRNAs is miR-9, which has also demonstrated to regulate HUVEC angiogenesis, proliferation, migration and invasion [241]. Additionally, people with GDM not only demonstrate dysregulated miR-222 expression in their placental tissue but also in their adipose tissue [216,223,242]. Interestingly, this miRNA is a key regulator of ER $\alpha$  expression in estrogen-induced insulin resistance [242]. miR-503 is another dysregulated miRNA found in the placenta of individuals with GDM [238]. This miRNA is involved in controlling inflammation-mediated angiogenesis, where its expression in HUVECs is up-regulated with high glucose [238,243–245]. As such, these findings provide potential connections between the maternal diabetic environment and placental vascular dysfunction. In addition to altered vascular function, various other hallmarks in the GDM placenta are known to be closely associated with altered fetal growth and therefore suggest possible mechanisms linking maternal diabetes to altered fetal growth [246–250].

GDM has also been associated with sexually dimorphic placental miRNA expression. In female pregnancies, these miRNAs are associated with pathways involving proteoglycans in cancer, protein processing in endoplasmic reticulum and signalling cascades which regulate vascular development, apoptosis and proliferation [57,251]. In contrast, male GDM pregnancies only demonstrate altered placental miRNA expression that is associated with extracellular



matrix–receptor interaction. As such, this suggests that the GDM environment has a more pronounced impact on the miRNA placental regulation of female pregnancies compared with male pregnancies [57,251].

## Aetiology of altered miRNA profiles in the placenta

The aetiology of altered placental miRNA expression in maternal diabetes remains unclear. One possible mechanism is that maternal diabetes may be characterised by aberrant miRNA biogenesis. Previous research shows placental Dicer dysregulation leads to changes in trophoblast proliferation, suggesting Dicer-dependent miRNAs are involved in regulating placental development [252]. Similar findings have been observed in the placentae of people with GDM, where Dicer, Drosha and DGCR8 expression are found to be altered, leading to changes in miRNA biogenesis [253]. Nonetheless, given that the majority of miRNAs are Dicer, Drosha and DGCR8-dependent miRNAs, this is unlikely to explain why only specific miRNAs are altered in the placenta of individuals with maternal diabetes. An alternative hypothesis is that high glucose levels, or other components of the diabetic environment, may be directly altering miRNA expression in the placenta and various maternal tissues. In turn, miRNAs may be important mediators between glucose fluctuations and downstream functional effects in the placenta. Of interest, many of the miRNAs with key roles in fetoplacental growth and regulation are known to be glucose sensitive, which is an important consideration in pregnancies complicated by maternal diabetes [173,175,177,179,180,254–257]. Not all studies report the status of maternal glucose control, however, variation in the placental hallmarks observed in T1DM, T2DM and GDM pregnancies suggests factors other than glucose may be involved. This is further evidenced by a previous report demonstrating that people with T1DM who have a well-controlled glycaemic profile manifest similar placental pathologies to those with sub-optimal glycaemic control [258]. Glucose-controlling agents such as metformin have demonstrated to impact miRNA expression in EVs and various *in vitro* and *in vivo* models [259–263]. With T2DM being associated with maternal adiposity and thus increased influence of lipids and adipokines [118], this further exemplifies the differences in the diabetic milieu across the various diabetic subtypes. Indeed, other maternal macro- and micronutrients that are altered in maternal diabetes, such as folate and vitamin B12 levels, have capacity to alter placental development and miRNA expression [264–266]. In addition, maternal ethnicity, diet, exercise, medication, infection, age, socioeconomic status and gestational age have all been identified as factors which influence placental miRNA regulation [267].

It is difficult to elucidate whether changes to the placental miRNA profile are a cause or a consequence of maternal diabetes in human clinical studies. *In vitro* findings show that mild hyperglycaemia directly alters the release of EV-miRNAs, which may explain why miRNAs are altered in the placenta and maternal circulation of pregnancies complicated by diabetes [268]. However, *in vivo* findings show that continued infusion of EVs from GDM pregnancies causes mice to develop glucose intolerance and altered tissue miRNA profile, compared with EVs from healthy pregnancies [269]. As such, these findings suggest that changes in miRNA regulation may be both a cause and a consequence of maternal diabetes.

Most studies to date have investigated the effects of GDM on placental miRNA profiling but not T1DM or T2DM. Given the difference in the underlying pathophysiology and clinical demographics of people with GDM, T1DM and T2DM, further research is required to profile placental miRNAs in all types of maternal diabetes [267].

## Circulating microRNAs

To our knowledge there are currently no published studies reporting miRNA profiles in the circulation of pregnant individuals with PGDM, however several EV-encompassed miRNAs have been shown to be altered in the maternal circulation in pregnancies complicated by GDM [200,270]. Whilst the tissue source of the majority of miRNAs in maternal circulation in GDM is unknown, it is likely that they originate from both maternal and placental tissue.

Indeed, this is supported by the observation that whilst individuals with GDM have lower circulating levels of placenta-derived small EVs compared with pregnant individuals without diabetes, overall, the level of EVs in maternal circulation is higher in GDM compared with those without diabetes [271]. This could suggest that the diabetic environment may be altering the release of various maternal organ EVs and their miRNA cargo into the circulation. Indeed, it has been shown that the hyperglycaemic component of the diabetic environment can modulate EV secretion and their miRNA cargo [195]. Some studies suggest that these changes in EV-miRNA cargo are protective adaptations against a hyperglycaemic environment [270]. However, it has also been postulated that EV-miRNAs may be involved in the pathogenesis of GDM where changes to EV-miRNA profiles have been detected in early pregnancy, prior to the diagnosis of GDM [200]. It has also been reported that maternal circulating miRNA expression in GDM pregnancies may differ depending on sex [272]. It remains to be established whether miRNAs that circulate to the placenta contribute towards altered placental development in pregnancies complicated by maternal diabetes, and if

so, whether they originate from specific maternal organs. Considering the tissue-of-origin of circulating miRNAs may help to delineate this.

Moreover, the proportional reduction in placenta-derived small EVs in the maternal circulation of individuals with GDM could also suggest that the diabetic environment reduces placental tissue EV release and biogenesis. Studies have shown that placenta-EV miRNA profile is altered in pregnant people with maternal diabetes. The functional effects of these miRNAs have been associated with cell proliferation, migration, angiogenesis, inflammation and glucose metabolism (Table 2) [199,200,273–276]. It remains to be established whether the effects of these placenta-derived EV-miRNAs in pregnancies complicated by maternal diabetes are limited to maternal organs or if they extend to fetal tissues. However, with placenta-derived EVs being able to interact with various maternal metabolic tissues and regulate maternal glucose homeostasis [194–196], it is possible that the altered placental EV release and miRNA content stimulated by the diabetic milieu may lead to changes in maternal metabolism and contribute towards GDM. Recent evidence shows that placenta-derived EVs from GDM pregnancies manifest an altered miRNA profile which is associated with aberrant insulin signalling and altered primary skeletal muscle cell insulin-stimulated migration and glucose uptake [199,200,276] (Table 2). As such, these findings suggest that placenta-derived EV-miRNAs likely play a role in influencing maternal metabolism in GDM.

Not only is the secretion and miRNA cargo of placenta-EVs affected by maternal diabetes, but evidence also suggests that EV production by maternal metabolic organs may be affected, which can in turn influence placental metabolism and maternal health in GDM [189]. Indeed, Nair et al. have demonstrated that continuous infusion of human maternal EVs from GDM pregnancies into healthy non-pregnant mice reduces pancreatic islet glucose-stimulated insulin secretion and promotes glucose intolerance, where skeletal muscle miRNA expression and glucose sensitivity are altered [277]. EVs derived from the adipose tissue of pregnant individuals with GDM have demonstrated to impact glucose metabolism in placental cells, causing alterations in glycolytic, gluconeogenic and glycogen storage processes [189]. While this study does not ascribe the effects of these adipose tissue-EVs to miRNA activity, glucose-sensitive miRNAs have been reported in adipose tissue which may impact insulin sensitivity [278]. In people with GDM, adipose tissue miRNA profile is altered; miR-222 was found to be up-regulated and suggested to be a key regulator of insulin resistance [242]. Placenta-derived EVs from individuals with GDM also showed altered expression levels of this miRNA [199]. Another recent study suggested that maternal visceral fat thickness may predict the risk of developing GDM via adipose tissue derived EV-miR-148 family signalling [279]. Interestingly, it has been previously reported that miR-148 is altered in placental tissue of those with GDM and T2DM, with its targets associated with insulin signalling and glucose metabolism [209]. As such, maternal diabetes has a significant influence on maternal organ EV-miRNA cargo which could contribute towards altered feto-placental development.

## **microRNAs and altered fetal growth in pregnancies complicated by maternal diabetes**

The miRNAome at the maternal–fetal interface has a direct influence on fetal growth and development [280–282]. Maternal diabetes impacts the maternal-fetal miRNAome by influencing placental miRNA expression and EV-mediated interorgan communication, which in turn has been linked to altered fetal growth [188,277]. Although lacking, a few studies have determined associations between fetal growth and miRNA expression levels in the maternal circulation and in placental tissue in pregnancies complicated by maternal diabetes (Table 3). The epidermal growth factor receptor (EGFR) pathway has been identified as a functional target of various miRNAs which are altered in the placenta of GDM pregnancies resulting in fetal overgrowth [283]. It is known that this signalling pathway plays a key role in placental and fetal development. As such, it is possible that the miRNAs identified to be associated with altered fetal growth in pregnancies complicated by maternal diabetes are key for regulating optimal fetal development (Table 3).

## **microRNAs and altered fetal development and offspring health in pregnancies complicated by maternal diabetes**

Maternal diabetes is associated with adverse offspring health outcomes, including an increased risk of developing cardiometabolic complications throughout life compared with offspring from uncomplicated pregnancies [25–27]. Increasing evidence suggests that maternal circulating factors may play a role in the development of these adverse adaptations. For example, it has been shown that injection of maternal EVs from diabetic mice into healthy pregnant mice contributes towards fetal cardiac developmental deficiency [287]. Similar findings have been demonstrated with fluorescently-labelled maternal EVs in a diabetic mouse model, where the maternal EVs were able to cross the placenta

and increase the risk of congenital heart defects in the offspring [288]. Although not specific to maternal diabetes, a recent investigation found that visceral adipose tissue EVs from obese mice contributed towards reduced fetal cardiac function in healthy lean pregnant mice by altering events in the placenta [289]. Although these studies do not investigate the role of EV-miRNA cargo contributing towards these adverse effects, increasing evidence supports the role of miRNAs in epigenetic programming and cardiovascular disease [290]. Indeed, studies have shown that offspring of pregnancies affected by maternal diabetes demonstrate altered fatty acid oxidation and glucose metabolism as a result of altered miRNA regulation [291,292]. Specifically, a recent pilot study has characterised a set of miRNAs associated with diabetes and cardiovascular disease to be dysregulated in the circulation of children exposed to GDM *in utero* [293]. Interestingly, many of these miRNAs have demonstrated to be altered in the maternal circulation and placental tissue of GDM pregnancies discussed in this review. Other animal studies have shown that baboon offspring exposed to GDM *in utero* also demonstrate altered cardiac miRNA expression, thereby increasing the risk of cardiac hypertrophy, myocardial infarction and cardiomyopathy [294]. Another study showed that fetal cardiac tissue from pregnant diabetic-induced mouse models demonstrated let-7e-5p, miR-139-5p, and miR-195-5p up-regulation and increased cardiac wall thickness [295].

Suboptimal maternal nutrition can impact offspring susceptibility to metabolic disease and cardiovascular dysfunction in a sex-specific manner [296–300]. Indeed, it has been shown that suboptimal maternal nutrition during pregnancy can programme offspring lipid metabolism and insulin resistance, thus contributing towards the development of T2DM [301]. GDM has been demonstrated to alter fetal lipid metabolism in a sex-dependent manner via miRNA activity, whereby the liver of male rat fetuses demonstrated down-regulated miR-130 expression, resulting in PPAR $\gamma$  up-regulation. Conversely, female rat fetal liver exclusively demonstrated miR-9 down-regulation and PPAR $\delta$  up-regulation in response to GDM [302]. The sex-specific influence of GDM on fetal hepatocyte miRNA regulation is becoming increasingly apparent, therefore our understanding of the contribution of miRNAs to the development of metabolic disorders, adipogenesis, obesity and fatty liver disease onset in offspring of GDM pregnancies is continuously progressing [303]. However, further research is needed to elucidate whether the sex-dependent effects on miRNA expression in male and female offspring of pregnancies complicated by maternal diabetes are due to increased vulnerability or advanced environmental adaptation to hyperglycaemia [251].

Evidence also suggests that miRNAs modulate fetal cerebrovascular development. It is theorised that dysregulation of miRNAs contributes to the increased risk of neurodevelopmental disorders in diabetic pregnancies [293,304,305]. To date, most studies investigating the effects of maternal diabetes on offsprings' long-term health have only focused on GDM. In recent years, it has become apparent that postpartum circulating EV-miRNA profile is altered in lactating individuals with T1DM, where dysregulated miRNAs have been associated with disease progression and inflammation, thus increasing offspring risk of immune-mediated diseases [306]. However, the long-term impact of maternal PGDM on offspring health and development requires further research.

## microRNAs and maternal cardiometabolic health in pregnancies complicated by maternal diabetes

GDM is known to increase the risk of adverse maternal outcomes, both during pregnancy and postpartum [307]. Preeclampsia is a frequent complication of pregnancies complicated by maternal diabetes; a condition known as high blood pressure and proteinuria during the third trimester of pregnancy which can lead to reduced placental blood flow, resulting in a lack of nutrient and oxygen exchange at the fetoplacental interface. As well as affecting the developing fetus, preeclampsia is associated with increased maternal risk of cardiovascular and cerebrovascular disease onset postpartum [308,309]. miRNAs may play a role in the pathophysiology of preeclampsia. Indeed, a dysregulated miRNA profile has been identified in preeclamptic placentae, where miR-106a~363 cluster expression is altered compared with healthy uncomplicated pregnancy [310]. C19MC miRNAs are also implicated in preeclampsia, where placental miR-516-5p, miR-517\*, miR-520a\*, miR-525 and miR-526 expression are up-regulated [311]. More recently, there is a call to further identify a robust miRNA biomarker profile that is uniquely altered in people with preeclampsia and determine whether their expression is resolved post-recovery [312].

Individuals with GDM are also at higher risk of developing T2DM postpartum [6]. It has been demonstrated that postpartum levels of several circulating miRNAs, including miR-16-5p, miR-17-5p, miR-29a-3p, miR-195-5p and miR-369-3p, are associated with postpartum diabetes onset in people with GDM [313,314]. In a 15-year follow-up study, circulating miR-24-3p expression, along with maternal weight and BMI, has also been associated with the future progression of dysglycaemia in individuals with GDM postpartum [315]. Interestingly, a mediterranean diet has demonstrated to improve insulin sensitivity and inflammation in people with GDM post-partum through the regulation of miR-222 and miR-103 [316]. Whilst the mechanism and relationship between miRNAs and postpartum

diabetes status remains to be established, the altered levels of miRNAs in circulation could potentially contribute towards reduced insulin sensitivity by influencing maternal organs, for example down-regulation of miR-369 has previously been reported in the pancreas in T2DM [317]. miR-24 expression levels have also been shown to both inversely correlate with HbA1C levels and to influence endothelial cell function in T2DM [318]. This corroborates with the observation that people with GDM have increased postpartum endothelial dysfunction [319], and various endothelial cell models demonstrating miRNA dysregulation under GDM conditions.

In addition to increased rates of T2DM following a GDM pregnancy, the risk of future cardiovascular diseases is increased by 2-fold for individuals diagnosed with GDM compared with those who experience healthy, uncomplicated pregnancies. This includes risk of stroke, ischemic heart disease and heart failure [320]. The mechanisms linking GDM to post-partum cardiac health remain to be established but 11 maternal circulating miRNAs (miR-13p, miR-20a-5p, miR-20b-5p, miR-23a-3p, miR-100-5p, miR-125b-5p, miR-126-3p, miR-181a-5p, miR-195-5p, miR-499a-5p and miR-574-3p) associated with cardiovascular disease have been found to be increased in the first trimester of GDM pregnancies compared with healthy uncomplicated pregnancy [321]. These findings therefore suggest that miRNAs may play a role in postpartum adverse maternal cardiometabolic health observed in GDM pregnancies; however, further studies are needed to establish the aetiology behind these associations.

## microRNAs in the diagnosis and management of pregnancies complicated by maternal diabetes

miRNAs have a clear role in the progression of maternal and fetal complications in pregnancies affected by maternal diabetes. Whilst further research is still needed to elucidate the pleiotropic effects and mechanisms of miRNAs, their biomarker potential to detect adverse maternal and fetal outcomes in pregnancies complicated by maternal diabetes is well-recognised. Not only do miRNAs increase understanding of underlying pathophysiology and altered target genes associated with diseases, but they may also provide an alternative means of non-invasive testing. GDM is usually diagnosed through an oral glucose tolerance test (OGTT) at weeks 24–28 gestation when pregnancy is at an advanced stage, meaning minimal interventions can be implemented to avoid or manage adverse maternal and fetal outcomes [72]. However, recent studies are suggesting that earlier detection and treatment is associated with better maternal and neonatal outcomes [322]. There is currently a lack of consensus on the gold standard diagnostic criteria that should be used for GDM, which has led to heterogeneous guidelines and confusion about the prevalence of GDM worldwide [323]. As such, many people with hyperglycaemia go undetected throughout pregnancy. There are certain maternal circulating miRNAs that have been identified as potential diagnostic biomarkers for GDM; however, intra-study reproducibility is an essential factor to consider when identifying miRNAs as biomarkers [72,324,325]. There are currently only six miRNAs (miR-195, miR-330, miR-342, miR-520h, miR-657, miR-1323) that have been similarly differentially expressed in people with GDM across multiple studies, with these studies using a range of methodologies and involving individuals of different populations and age range [267]. Most of these miRNAs have been identified to be altered in the placenta of people with GDM (Table 1). Using miRNAs as biomarkers for GDM diagnosis would provide another layer of screening for improved consensus [267]. This would allow for adverse maternal and fetal outcomes to be detected at an earlier stage of pregnancy and thus allow more time for intervention strategies to be implemented, such as exercise, diet and medication [72]. It has been shown that exercise during pregnancy can alter the plasma miRNA profile in individuals with GDM, giving rise to potential biomarkers that may be used to detect GDM risk [326]. Evidence also suggests that maternal exercise during pregnancy may improve female offspring hepatic metabolism by modulating miRNA activity and reverse the dysregulated fetal cardiac miRNA profile identified in GDM pregnancies [327,328].

Since maternal diabetes increases the risk of neonates being classed as LGA and predisposes them to cardiometabolic complications throughout life, infants of pregnancies complicated by maternal diabetes would benefit from primary prevention strategies. Identifying pregnancies at risk LGA would also allow suitable birth planning and improved clinical management of mother and offspring throughout pregnancy. Additionally, follow-up screening of the neonatal miRNA profile may provide better identification of congenital abnormalities that are associated with pregnancies complicated by maternal diabetes, such as cardiovascular and cerebrovascular complications [293]. Maternal diabetes is also associated with an increased risk of postpartum maternal cardiometabolic disease and cancer. Thus, identifying the altered maternal miRNA profiles associated with these complications would also improve clinical management of maternal health after pregnancy.

Currently, there is a lack of study reproducibility of miRNAs being used as biomarkers. Sample collection, storage, isolation and processing methodologies all influence miRNA quality and stability [329–331]. Therefore, improving consensus on the appropriate methods to use for miRNA biomarker studies would increase reproducibility.



## Conclusion

miRNAs play a key role in regulating optimal placental and fetal development during pregnancy, with their dysregulation contributing towards altered placental growth and metabolism in pregnancies complicated by maternal diabetes. To date, the vast majority of studies have focused on the effect of GDM on the placental miRNA profile; however with their unique underlying placental pathophysiology, future studies should further investigate the effects of T1DM and T2DM on placental miRNA expression. Moreover, not only do miRNAs have a direct effect on placental regulation and fetal development during pregnancy, but they may also serve as potential biomarkers for health disorders in offspring. Increasing evidence also suggests circulating miRNAs may predict maternal risk of developing GDM and adverse outcomes postpartum. However, further research is needed to improve the reproducibility of miRNAs as biomarkers in pregnancies complicated by maternal diabetes. With maternal diabetes being associated with suboptimal placental development, altered fetal growth and adverse health outcomes for mother and offspring, miRNAs provide a non-invasive screening alternative into disease pathology and improved clinical management of maternal and fetal health during pregnancy.

## Data Availability

No new data were generated or analysed in support of this research.

## Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

## Funding

M.D.O. is funded by British Heart Foundation 4-year PhD studentship [grant number FS/4yPhD/F/20/34130]; M.G.K. was funded by a Mary & Alice Smith Memorial Scholarship from University of Leeds. This work was also supported by grants from UK Research and Innovation (UKRI) Medical Research Council [grant numbers MR/R023166/1 (to K.F.) and MR/Y003659/1 (to K.F. and E.M.S.)].

## Open Access

Open access for this article was enabled by the participation of University of Leeds in an all-inclusive *Read & Publish* agreement with Portland Press and the Biochemical Society under a transformative agreement with JISC.

## CRedit Author Contribution

**Manon D. Owen:** Data curation, Formal analysis, Investigation, Methodology, Writing—original draft, Writing—review & editing. **Margeurite G. Kennedy:** Data curation, Investigation, Methodology, Writing—original draft, Writing—review & editing. **Rachel C. Quilang:** Supervision, Writing—review & editing. **Eleanor M. Scott:** Conceptualization, Supervision, Funding acquisition, Investigation, Project administration, Writing—review & editing. **Karen Forbes:** Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing—original draft, Project administration, Writing—review & editing.

## Abbreviations

BM, basal plasma membrane; C19MC, chromosome 19 miRNA cluster; CGM, continuous glucose monitoring; EOT2D, early onset T2DM; EV, extracellular vesicle; FATP, fatty acid transport protein; GLP-1, glucagon-like peptide-1; OGTT, oral glucose tolerance test; SNAT, sodium-coupled neutral amino acid transporter; T1DM, Type 1 diabetes mellitus; T2DM, Type 2 diabetes mellitus.

## References

- 1 International Diabetes Federation (2021) *IDF Diabetes Atlas*, 10th edn, Brussels Belgium, Available from: <https://www.diabetesatlas.org>, accessed: 1 February 2024.
- 2 Ornoy, A., Reece, E.A., Pavlinkova, G., Kappen, C. and Miller, R.K. (2015) Effect of maternal diabetes on the embryo, fetus, and children: Congenital anomalies, genetic and epigenetic changes and developmental outcomes. *Birth Defects Res. C Embryo Today* **105**, 53–72, <https://doi.org/10.1002/bdrc.21090>
- 3 Memon, S., Ahsan, S., Riaz, Q., Basit, A., Sheikh, S.A., Fawwad, A. et al. (2014) Frequency of severity and risk indicators retinopathy in patients with diabetes screened by fundus photographs: a study from primary health care. *Pak. J. Med. Sci.* **30** (2), 366–372
- 4 Fong, A., Serra, A., Herrero, T., Pan, D. and Ogunyemi, D. (2014) Pre-gestational versus gestational diabetes: a population based study on clinical and demographic differences. *J. Diabetes Complications* **28**, 29–34, <https://doi.org/10.1016/j.jdiacomp.2013.08.009>

- 5 Sugiyama, T., Saito, M., Nishigori, H., Nagase, S., Yaegashi, N., Sagawa, N. et al. (2014) Comparison of pregnancy outcomes between women with gestational diabetes and overt diabetes first diagnosed in pregnancy: a retrospective multi-institutional study in Japan. *Diabetes Res. Clin. Pract.* **103**, 20–25, <https://doi.org/10.1016/j.diabres.2013.10.020>
- 6 Bellamy, L., Casas, J.P., Hingorani, A.D. and Williams, D. (2009) Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *Lancet North Am. Ed.* **373**, 1773–1779, [https://doi.org/10.1016/S0140-6736\(09\)60731-5](https://doi.org/10.1016/S0140-6736(09)60731-5)
- 7 Billionnet, C., Mitanchez, D., Weill, A., Nizard, J., Alla, F., Hartemann, A. et al. (2017) Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012. *Diabetologia* **60**, 636–644, <https://doi.org/10.1007/s00125-017-4206-6>
- 8 Weissgerber, T.L. and Mudd, L.M. (2015) Preeclampsia and diabetes. *Curr. Diab. Rep.* **15** (3), 9, <https://doi.org/10.1007/s11892-015-0579-4>
- 9 Phipps, E., Prasanna, D., Brima, W. and Jim, B. (2016) Preeclampsia: updates in pathogenesis, definitions, and guidelines. *Clin. J. Am. Soc. Nephrol.* **11**, 1102–1113, <https://doi.org/10.2215/CJN.12081115>
- 10 KC, K., Shakya, S. and Zhang, H. (2015) Gestational diabetes mellitus and macrosomia: a literature review. *Ann. Nutr. Metab.* **66**, 14–20, <https://doi.org/10.1159/000371628>
- 11 Mikolajczyk, R.T., Zhang, J., Betran, A.P., Souza, J.P., Mori, R., Gülmezoglu, A.M. et al. (2011) A global reference for fetal-weight and birthweight percentiles. *Lancet North Am. Ed.* **377**, 1855–1861, [https://doi.org/10.1016/S0140-6736\(11\)60364-4](https://doi.org/10.1016/S0140-6736(11)60364-4)
- 12 Cyganek, K., Skupien, J., Katra, B., Hebda-Szydlo, A., Janas, I., Trznadel-Morawska, I. et al. (2017) Risk of macrosomia remains glucose-dependent in a cohort of women with pregestational type 1 diabetes and good glycemic control. *Endocrine* **55**, 447–455, <https://doi.org/10.1007/s12020-016-1134-z>
- 13 de Valk, H.W., van Nieuwaal, N.H.G. and Visser, G.H.A. (2006) Pregnancy outcome in Type 2 diabetes mellitus: a retrospective analysis from the Netherlands. *Rev. Diab. Studies* **3**, 134–134, <https://doi.org/10.1900/RDS.2006.3.134>
- 14 Dunne, F., Owens, L.A., Avalos, G., Denny, C., O'Sullivan, E.P. and O'Reilly, M. (2011) Gestational diabetes mellitus results in a higher prevalence of small for gestational babies. *43rd Annual Meeting of DPSG Cambridge*, Diabetic Study Pregnancy Group (DSPG)
- 15 Mohammad, N., Sohaila, A., Rabbani, U., Ahmed, S., Ahmed, S. and Rehan Ali, S. (2018) Maternal predictors of intrauterine growth retardation. *J. College Physicians Surgeons Pakistan* **28**, 681–685, <https://doi.org/10.29271/jcpsp.2018.09.681>
- 16 Bamfo, J.E.A.K. and Odibo, A.O. (2011) Diagnosis and management of fetal growth restriction. *J. Pregnancy* **2011**, 1–15, <https://doi.org/10.1155/2011/640715>
- 17 McCance, D.R. (2015) Diabetes in pregnancy. *Best Pract. Res. Clin. Obstet. Gynaecol.* **29**, 685–699, <https://doi.org/10.1016/j.bpobgyn.2015.04.009>
- 18 Armengaud, J.B., Ma, R.C.W., Siddeek, B., Visser, G.H.A. and Simeoni, U. (2018) Offspring of mothers with hyperglycaemia in pregnancy: the short term and long-term impact. What is new? *Diabetes Res. Clin. Pract.* **145**, 155–166, <https://doi.org/10.1016/j.diabres.2018.07.039>
- 19 Mitanchez, D., Zydorczyk, C., Siddeek, B., Boubred, F., Benahmed, M. and Simeoni, U. (2015) The offspring of the diabetic mother - Short- and long-term implications. *Best Pract. Res. Clin. Obstet. Gynaecol.* **29**, 256–269, <https://doi.org/10.1016/j.bpobgyn.2014.08.004>
- 20 Barker, D.J.P. (2004) The developmental origins of adult disease. *J. Am. Coll. Nutr.* **23**, 588S–595S, <https://doi.org/10.1080/07315724.2004.10719428>
- 21 Calkins, K. and Devaskar, S.U. (2011) Fetal origins of adult disease. *Curr. Probl. Pediatr. Adolesc. Health Care* **41**, 158–176, <https://doi.org/10.1016/j.cppeds.2011.01.001>
- 22 Lane, R.H. (2014) Fetal programming, epigenetics, and adult onset disease. *Clin. Perinatol.* **41**, 815–831, <https://doi.org/10.1016/j.clp.2014.08.006>
- 23 Knop, M.R., Geng, T., Gorny, A.W., Ding, R., Li, C., Ley, S.H. et al. (2018) Birth weight and risk of Type 2 diabetes mellitus, cardiovascular disease, and hypertension in adults: a meta-analysis of 7 646 267 participants from 135 studies. *J. Am. Heart Assoc.* **7** (23), e008870, <https://doi.org/10.1161/JAHA.118.008870>
- 24 Barker, D.J., Bull, A.R., Osmond, C. and Simmonds, S.J. (1990) Fetal and placental size and risk of hypertension in adult life. *BMJ* **301**, 259–262, <https://doi.org/10.1136/bmj.301.6746.259>
- 25 Lowe, W.L., Lowe, L.P., Kuang, A., Catalano, P.M., Nodzenski, M., Talbot, O. et al. (2019) Maternal glucose levels during pregnancy and childhood adiposity in the Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study. *Diabetologia* **62**, 598–610, <https://doi.org/10.1007/s00125-018-4809-6>
- 26 Lowe, W.L., Scholtens, D.M., Kuang, A., Linder, B., Lawrence, J.M., Lebenthal, Y. et al. (2019) Hyperglycemia and adverse pregnancy outcome follow-up study (HAPO FUS): maternal gestational diabetes mellitus and childhood glucose metabolism. *Diabetes Care* **42**, 372–380, <https://doi.org/10.2337/dc18-1646>
- 27 Wroblewska-Seniuk, K., Wender-Ozegowska, E. and Szczapa, J. (2009) Long-term effects of diabetes during pregnancy on the offspring. *Pediatr. Diabetes* **10**, 432–440, <https://doi.org/10.1111/j.1399-5448.2009.00507.x>
- 28 Platt, M.J. (2014) Outcomes in preterm infants. *Public Health* **128**, 399–403, <https://doi.org/10.1016/j.puhe.2014.03.010>
- 29 Owen, M.D., Baker, B.C., Scott, E.M. and Forbes, K. (2021) Interaction between metformin, folate and vitamin B12 and the potential impact on fetal growth and long-term metabolic health in diabetic pregnancies. *Int. J. Mol. Sci.* **22**, 5759, <https://doi.org/10.3390/ijms22115759>
- 30 Yu, Q., Aris, I.M., Tan, K.H. and Li, L.J. (2019) Application and utility of continuous glucose monitoring in pregnancy: a systematic review. *Front. Endocrinol. (Lausanne)* **10**, 697, <https://doi.org/10.3389/fendo.2019.00697>
- 31 Scott, E.M., Murphy, H.R., Kristensen, K.H., Feig, D.S., Kjölhede, K., Englund-Ögge, L. et al. (2022) Continuous glucose monitoring metrics and birth weight: informing management of type 1 diabetes throughout pregnancy. *Diabetes Care* **45**, 1724–1734, <https://doi.org/10.2337/dc22-0078>
- 32 Stewart, Z.A., Wilinska, M.E., Hartnell, S., Temple, R.C., Rayman, G., Stanley, K.P. et al. (2016) Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. *N. Engl. J. Med.* **375**, 644–654, <https://doi.org/10.1056/NEJMoa1602494>
- 33 Stacey, T. and Tennant, P. (2019) Gestational diabetes and the risk of late stillbirth: a case-control study from England, UK. *BJOG* **126**, 1184–1184, <https://doi.org/10.1111/1471-0528.15810>

- 34 Tarry-Adkins, J.L., Aiken, C.E. and Ozanne, S.E. (2019) Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: a systematic review and meta-analysis. *PLoS Med.* **16**, e1002848, <https://doi.org/10.1371/journal.pmed.1002848>
- 35 Li, L.J., Huang, L., Tobias, D.K. and Zhang, C. (2022) Gestational diabetes mellitus among asians - a systematic review from a population health perspective. *Front. Endocrinol. (Lausanne)* **13**, 840331, <https://doi.org/10.3389/fendo.2022.840331>
- 36 Plows, J., Stanley, J., Baker, P., Reynolds, C. and Vickers, M. (2018) The pathophysiology of gestational diabetes mellitus. *Int. J. Mol. Sci.* **19**, 3342, <https://doi.org/10.3390/ijms19113342>
- 37 Balsells, M., Garcia-Patterson, A., Gich, I. and Corcoy, R. (2009) Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. *J. Clin. Endocrinol. Metab.* **94**, 4284–4291, <https://doi.org/10.1210/jc.2009-1231>
- 38 National Health Service (NHS) (2021) National Pregnancy in Diabetes Audit Report 2020. Available from: <https://digital.nhs.uk/data-and-information/publications/statistical/national-pregnancy-in-diabetes-audit/2019-and-2020>
- 39 Lapehn, S. and Paquette, A.G. (2022) The placental epigenome as a molecular link between prenatal exposures and fetal health outcomes through the DOHaD hypothesis. *Curr. Environ. Health Rep.* **9**, 490–501, <https://doi.org/10.1007/s40572-022-00354-8>
- 40 Jansson, T. and Powell, T.L. (2007) Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches. *Clin. Sci.* **113**, 1–13, <https://doi.org/10.1042/CS20060339>
- 41 Desforges, M. and Sibley, C.P. (2010) Placental nutrient supply and fetal growth. *Int. J. Dev. Biol.* **54**, 377–390, <https://doi.org/10.1387/ijdb.082765md>
- 42 Byford, A., Baird-Rayner, C. and Forbes, K. (2021) Don't sugar coat it: the effects of gestational diabetes on the placental vasculature. *Biochem. (Lond.)* **43**, 34–39, <https://doi.org/10.1042/bio2021117>
- 43 Aplin, J.D., Lewis, R.M. and Jones, C.J.P. (2018) Development of the human placental villus. *Reference Module in Biomedical Sciences*, Elsevier, <https://doi.org/10.1016/B978-0-12-801238-3.99857-X>
- 44 Fisher, J.J., McKeating, D.R., Cuffe, J.S., Bianco-Miotto, T., Holland, O.J. and Perkins, A.V. (2019) Proteomic analysis of placental mitochondria following trophoblast differentiation. *Front Physiol.* **10**, 1536, <https://doi.org/10.3389/fphys.2019.01536>
- 45 Bustamante, J., Ramírez-Vélez, R., Czerniczyniec, A., Cicerchia, D., Aguilar de Plata, A.C. and Lores-Arnaiz, S. (2014) Oxygen metabolism in human placenta mitochondria. *J. Bioenerg. Biomembr.* **46**, 459–469, <https://doi.org/10.1007/s10863-014-9572-x>
- 46 Forbes, K., Westwood, M., Baker, P.N. and Aplin, J.D. (2008) Insulin-like growth factor I and II regulate the life cycle of trophoblast in the developing human placenta. *Am. J. Physiol.-Cell Physiol.* **294**, C1313–C1322, <https://doi.org/10.1152/ajpcell.00035.2008>
- 47 Forbes, K. and Westwood, M. (2010) Maternal growth factor regulation of human placental development and fetal growth. *J. Endocrinol.* **207**, 1–16, <https://doi.org/10.1677/JOE-10-0174>
- 48 Farrokhnia, F., Aplin, J.D., Westwood, M. and Forbes, K. (2014) MicroRNA regulation of mitogenic signaling networks in the human placenta. *J. Biol. Chem.* **289**, 30404–30416, <https://doi.org/10.1074/jbc.M114.587295>
- 49 Burton, G.J., Charnock-Jones, D.S. and Jauniaux, E. (2009) Regulation of vascular growth and function in the human placenta. *Reproduction* **138**, 895–902, <https://doi.org/10.1530/REP-09-0092>
- 50 Simpson, R.A., Mayhew, T.M. and Barnes, P.R. (1992) From 13 weeks to term, the trophoblast of human placenta grows by the continuous recruitment of new proliferative units: A study of nuclear number using the dissector. *Placenta* **13**, 501–512, [https://doi.org/10.1016/0143-4004\(92\)90055-X](https://doi.org/10.1016/0143-4004(92)90055-X)
- 51 Costa, M.A. (2016) The endocrine function of human placenta: an overview. *Reprod. Biomed. Online* **32**, 14–43, <https://doi.org/10.1016/j.rbmo.2015.10.005>
- 52 Lager, S. and Powell, T.L. (2012) Regulation of nutrient transport across the placenta. *J. Pregnancy* **2012**, 1–14, <https://doi.org/10.1155/2012/179827>
- 53 Baumann, M.U., Deborde, S. and Illsley, N.P. (2002) Placental glucose transfer and fetal growth. *Endocrine* **19**, 13–22, <https://doi.org/10.1385/ENDO:19:1:13>
- 54 Castillo-Castrejon, M. and Powell, T.L. (2017) Placental nutrient transport in gestational diabetic pregnancies. *Front Endocrinol. (Lausanne)* **8**, <https://doi.org/10.3389/fendo.2017.00306>
- 55 Gaccioli, F. and Lager, S. (2016) Placental nutrient transport and intrauterine growth restriction. *Front Physiol.* **7**, <https://doi.org/10.3389/fphys.2016.00040>
- 56 Olney, K.C., Plaisier, S.B., Phung, T.N., Silasi, M., Perley, L., O'Bryan, J. et al. (2022) Sex differences in early and term placenta are conserved in adult tissues. *Biol. Sex Differ.* **13**, <https://doi.org/10.1186/s13293-022-00470-y>
- 57 Vari, R., Scazzocchio, B., Filardi, T., Citarella, A., Bellenghi, M., Masella, R. et al. (2021) Significance of sex differences in ncRNAs expression and function in pregnancy and related complications. *Biomedicines* **9**, 1509, <https://doi.org/10.3390/biomedicines9111509>
- 58 Leach, L., Taylor, A. and Sciota, F. (2009) Vascular dysfunction in the diabetic placenta: causes and consequences. *J. Anat.* **215**, 69–76, <https://doi.org/10.1111/j.1469-7580.2009.01098.x>
- 59 Desoye, G. and Hauguel-de Mouzon, S. (2007) The human placenta in gestational diabetes mellitus. *Diabetes Care.* **30**, S120–S126, <https://doi.org/10.2337/dc07-s203>
- 60 Jirkovsk, M. (2012) The morphology of villous capillary bed in normal and diabetic placenta. *Recent Advances in Research on the Human Placenta*, InTech, <https://doi.org/10.5772/32155>
- 61 Burton, G.J. and Jauniaux, E. (2018) Development of the human placenta and fetal heart: synergic or independent? *Front Physiol.* **9**, <https://doi.org/10.3389/fphys.2018.00373>
- 62 Evers, I.M., Nikkels, P.G.J., Sikkema, J.M. and Visser, G.H.A. (2003) Placental pathology in women with type 1 diabetes and in a control group with normal and large-for-gestational-age infants. *Placenta* **24**, 819–825, [https://doi.org/10.1016/S0143-4004\(03\)00128-0](https://doi.org/10.1016/S0143-4004(03)00128-0)
- 63 Huynh, J., Dawson, D., Roberts, D. and Bentley-Lewis, R. (2015) A systematic review of placental pathology in maternal diabetes mellitus. *Placenta* **36**, 101–114, <https://doi.org/10.1016/j.placenta.2014.11.021>

- 64 Huynh, J., Yamada, J., Beauharnais, C., Wenger, J.B., Thadhani, R.I., Wexler, D. et al. (2015) Type 1, type 2 and gestational diabetes mellitus differentially impact placental pathologic characteristics of uteroplacental malperfusion. *Placenta* **36**, 1161–1166, <https://doi.org/10.1016/j.placenta.2015.08.004>
- 65 Pietryga, M., Brazert, J., Wender-Oęowska, E., Biczysko, R., Dubiel, M. and Gudmundsson, S. (2005) Abnormal Uterine doppler is related to vasculopathy in pregestational diabetes mellitus. *Circulation* **112**, 2496–2500, <https://doi.org/10.1161/CIRCULATIONAHA.104.492843>
- 66 Vajnerova, O., Kafka, P., Kratzerova, T., Chalupsky, K. and Hampl, V. (2018) Pregestational diabetes increases fetoplacental vascular resistance in rats. *Placenta* **63**, 32–38, <https://doi.org/10.1016/j.placenta.2018.01.008>
- 67 Eriksson, U.J. and Jansson, L. (1984) Diabetes in pregnancy: decreased placental blood flow and disturbed fetal development in the rat. *Pediatr. Res.* **18**, 735–738, <https://doi.org/10.1203/00006450-198408000-00012>
- 68 Rizzo, G., Mappa, I., Bitsadze, V., Ślodki, M., Khizroeva, J., Makatsariya, A. et al. (2020) Role of first-trimester umbilical vein blood flow in predicting large-for-gestational age at birth. *Ultrasound Obstetrics Gynecol.* **56**, 67–72, <https://doi.org/10.1002/uog.20408>
- 69 Ferrazzi, E., Bulfamante, G., Mezzopane, R., Barbera, A., Ghidini, A. and Pardi, G. (1999) Uterine Doppler velocimetry and placental hypoxic-ischemic lesion in pregnancies with fetal intrauterine growth restriction. *Placenta* **20**, 389–394, <https://doi.org/10.1053/plac.1999.0395>
- 70 Salavati, N., Sovio, U., Mayo, R.P., Charnock-Jones, D.S. and Smith, G.C.S. (2016) The relationship between human placental morphometry and ultrasonic measurements of utero-placental blood flow and fetal growth. *Placenta* **38**, 41–48, <https://doi.org/10.1016/j.placenta.2015.12.003>
- 71 Browne, V.A., Julian, C.G., Toledo-Jaldin, L., Cioffi-Ragan, D., Vargas, E. and Moore, L.G. (2015) Uterine artery blood flow, fetal hypoxia and fetal growth. *Philosophical Transact. Royal Soc. B: Biological Sci.* **370**, 20140068, <https://doi.org/10.1098/rstb.2014.0068>
- 72 Cao, Y., Jia, Y., Xing, B., Shi, D. and Dong, X. (2017) Plasma microRNA-16-5p, -17-5p and -20a-5p: Novel diagnostic biomarkers for gestational diabetes mellitus. *J. Obstet. Gynaecol. Res.* **43**, 974–981, <https://doi.org/10.1111/jog.13317>
- 73 McIntyre, H.D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E.R. and Damm, P. (2019) Gestational diabetes mellitus. *Nat. Rev. Dis. Primers* **5**, 47, <https://doi.org/10.1038/s41572-019-0098-8>
- 74 Stern, C., Schwarz, S., Moser, G., Cvitic, S., Jantscher-Krenn, E., Gauster, M. et al. (2021) Placental endocrine activity: adaptation and disruption of maternal glucose metabolism in pregnancy and the influence of fetal sex. *Int. J. Mol. Sci.* **22**, 12722, <https://doi.org/10.3390/ijms222312722>
- 75 Talbot, C.P.J. and Dolinsky, V.W. (2019) Sex differences in the developmental origins of cardiometabolic disease following exposure to maternal obesity and gestational diabetes. *Appl. Physiol. Nutr. Metab.* **44**, 687–695, <https://doi.org/10.1139/apnm-2018-0667>
- 76 Hu, J., Ge, Z., Xu, Q., Shen, S., Wang, Y., Zhu, D. et al. (2020) Influence of fetal sex on perinatal outcomes in women with gestational diabetes mellitus. *Diabetes Metab. Res. Rev.* **36**, e3245, <https://doi.org/10.1002/dmrr.3245>
- 77 Du, Q., Sompolinsky, Y., Walfisch, A., Zhong, H., Liu, Y. and Feng, W. (2020) The sex specific association between maternal gestational diabetes and offspring metabolic status at 1 year of age. *Front Endocrinol. (Lausanne)* **11**, 608125, <https://doi.org/10.3389/fendo.2020.608125>
- 78 Retnakaran, R. and Shah, B.R. (2015) Fetal sex and the natural history of maternal risk of diabetes during and after pregnancy. *J. Clin. Endocrinol. Metab.* **100**, 2574–2580, <https://doi.org/10.1210/jc.2015-1763>
- 79 Gauster, M., Desoye, G., Tötsch, M. and Hiden, U. (2012) The placenta and gestational diabetes mellitus. *Curr. Diab. Rep.* **12**, 16–23, <https://doi.org/10.1007/s11892-011-0244-5>
- 80 Desoye, G. and Shafir, E. (1996) The human placenta in diabetic pregnancy. *Diab. Rev.* **4**, 70–89
- 81 Daskalakis, G., Marinopoulos, S., Krielesi, V., Papapanagiotou, A., Papantoniou, N., Mesogitis, S. et al. (2008) Placental pathology in women with gestational diabetes. *Acta Obstet. Gynecol. Scand.* **87**, 403–407, <https://doi.org/10.1080/00016340801908783>
- 82 Carrasco-Wong, I., Moller, A., Giachini, F.R., Lima, V.V., Toledo, F., Stojanova, J. et al. (2020) Placental structure in gestational diabetes mellitus. *Biochim. Biophys. Acta* **1866**, 165535, <https://doi.org/10.1016/j.bbadis.2019.165535>
- 83 Aldahmash, W.M., Alwasel, S.H. and Algerian, K. (2022) Gestational diabetes mellitus induces placental vasculopathies. *Environ. Sci. Pollution Res.* **29**, 19860–19868, <https://doi.org/10.1007/s11356-021-17267-y>
- 84 Enquobahrie, D.A., Williams, M.A., Qiu, C., Meller, M. and Sorensen, T.K. (2009) Global placental gene expression in gestational diabetes mellitus. *Am. J. Obstet. Gynecol.* **200**, 206.e1–206.e13, <https://doi.org/10.1016/j.ajog.2008.08.022>
- 85 Rong, C., Cui, X., Chen, J., Qian, Y., Jia, R. and Hu, Y. (2015) DNA methylation profiles in placenta and its association with gestational diabetes mellitus. *Exp. Clin. Endocrinol. Diab.* **123**, 282–288, <https://doi.org/10.1055/s-0034-1398666>
- 86 Reichetzeder, C., Dwi Putra, S.E., Pfab, T., Slowinski, T., Neuber, C., Kleuser, B. et al. (2016) Increased global placental DNA methylation levels are associated with gestational diabetes. *Clin. Epigenetics* **8**, 82, <https://doi.org/10.1186/s13148-016-0247-9>
- 87 Coughlan, M.T., Vervaart, P.P., Permezel, M., Georgiou, H.M. and Rice, G.E. (2004) Altered placental oxidative stress status in gestational diabetes mellitus. *Placenta* **25**, 78–84, [https://doi.org/10.1016/S0143-4004\(03\)00183-8](https://doi.org/10.1016/S0143-4004(03)00183-8)
- 88 Pan, X., Jin, X., Wang, J., Hu, Q. and Dai, B. (2021) Placenta inflammation is closely associated with gestational diabetes mellitus. *Am. J. Transl. Res.* **13**, 4068–4079
- 89 Yu, J., Zhou, Y., Gui, J., Li, A.-Z., Su, X.-L. and Feng, L. (2013) Assessment of the number and function of macrophages in the placenta of gestational diabetes mellitus patients. *J. Huazhong University Sci. Technol. [Medical Sciences]* **33**, 725–729, <https://doi.org/10.1007/s11596-013-1187-7>
- 90 Magee, T.R., Ross, M.G., Wedekind, L., Desai, M., Kjos, S. and Belkacemi, L. (2014) Gestational diabetes mellitus alters apoptotic and inflammatory gene expression of trophoblasts from human term placenta. *J. Diabetes Compl.* **28**, 448–459, <https://doi.org/10.1016/j.jdiacomp.2014.03.010>
- 91 Biri, A., Onan, A., Devrim, E., Babacan, F., Kavutcu, M. and Durak, İ. (2006) Oxidant status in maternal and cord plasma and placental tissue in gestational diabetes. *Placenta* **27**, 327–332, <https://doi.org/10.1016/j.placenta.2005.01.002>
- 92 Li, Y.-X., Long, D.-L., Liu, J., Qiu, D., Wang, J., Cheng, X. et al. (2020) Gestational diabetes mellitus in women increased the risk of neonatal infection via inflammation and autophagy in the placenta. *Medicine (Baltimore)* **99**, e22152, <https://doi.org/10.1097/MD.00000000000022152>
- 93 Fisher, J.J., Vanderpeet, C.L., Bartho, L.A., McKeating, D.R., Cuffe, J.S.M., Holland, O.J. et al. (2021) Mitochondrial dysfunction in placental trophoblast cells experiencing gestational diabetes mellitus. *J. Physiol.* **599**, 1291–1305, <https://doi.org/10.1113/JP280593>



- 94 Keckstein, S., Pritz, S., Amann, N., Meister, S., Beyer, S., Jegen, M. et al. (2020) Sex specific expression of interleukin 7, 8 and 15 in placentas of women with gestational diabetes. *Int. J. Mol. Sci.* **21**, 8026, <https://doi.org/10.3390/ijms21218026>
- 95 Ren, Z.-R., Luo, S.-S., Qin, X.-Y., Huang, H.-F. and Ding, G.-L. (2024) Sex-specific alterations in placental proteomics induced by intrauterine hyperglycemia. *J. Proteome Res.* **23**, 1272–1284, <https://doi.org/10.1021/acs.jproteome.3c00735>
- 96 Jiang, S., Teague, A.M., Tryggstad, J.B., Aston, C.E., Lyons, T. and Chernausk, S.D. (2017) Effects of maternal diabetes and fetal sex on human placenta mitochondrial biogenesis. *Placenta* **57**, 26–32, <https://doi.org/10.1016/j.placenta.2017.06.001>
- 97 Cui, Y., Cruz, M., Palatnik, A. and Olivier-Van Stichelen, S. (2023) O-GlcNAc transferase contributes to sex-specific placental deregulation in gestational diabetes. *Placenta* **131**, 1–12, <https://doi.org/10.1016/j.placenta.2022.11.006>
- 98 Katsarou, A., Gudbjörnsdóttir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B.J. et al. (2017) Type 1 diabetes mellitus. *Nat. Rev. Dis. Primers* **3**, 17016, <https://doi.org/10.1038/nrdp.2017.16>
- 99 Jirkovská, M., Kučera, T., Kaláb, J., Jadrniček, M., Niedobová, V., Janáček, J. et al. (2012) The branching pattern of villous capillaries and structural changes of placental terminal villi in type 1 diabetes mellitus. *Placenta* **33**, 343–351, <https://doi.org/10.1016/j.placenta.2012.01.014>
- 100 Higgins, M., Felle, P., Mooney, E.E., Bannigan, J. and McAuliffe, F.M. (2011) Stereology of the placenta in type 1 and type 2 diabetes. *Placenta* **32**, 564–569, <https://doi.org/10.1016/j.placenta.2011.04.015>
- 101 Whittington, J.R., Cummings, K.F., Ounpraseuth, S.T., Aughenbaugh, A.L., Quick, C.M. and Dajani, N.K. (2022) Placental changes in diabetic pregnancies and the contribution of hypertension. *J. Maternal-Fetal Neonatal Med.* **35**, 486–494, <https://doi.org/10.1080/14767058.2020.1724944>
- 102 Stanirowski, P.J., Szukiewicz, D., Majewska, A., Wałroba, M., Pyzlak, M., Bomba-Opoń, D. et al. (2022) Placental expression of glucose transporters GLUT-1, GLUT-3, GLUT-8 and GLUT-12 in pregnancies complicated by gestational and type 1 diabetes mellitus. *J. Diab. Investig.* **13**, 560–570, <https://doi.org/10.1111/jdi.13680>
- 103 Radaelli, T., Lepercq, J., Varastehpour, A., Basu, S., Catalano, P.M. and Hauguel-De Mouzon, S. (2009) Differential regulation of genes for fetoplacental lipid pathways in pregnancy with gestational and type 1 diabetes mellitus. *Am. J. Obstet. Gynecol.* **201**, 209.e1–209.e10, <https://doi.org/10.1016/j.ajog.2009.04.019>
- 104 Majali-Martinez, A., Weiss-Fuchs, U., Miedl, H., Forstner, D., Bandres-Meriz, J., Hoch, D. et al. (2021) Type 1 Diabetes mellitus and the first trimester placenta: hyperglycemia-induced effects on trophoblast proliferation, cell cycle regulators, and invasion. *Int. J. Mol. Sci.* **22** (20), 10989, <https://doi.org/10.3390/ijms222010989>
- 105 Xie, L., Galetti, A., Morris, J., Jackson, C., Twigg, S.M. and Gallery, E.D.M. (2008) Intercellular adhesion molecule-1 (ICAM-1) expression is necessary for monocyte adhesion to the placental bed endothelium and is increased in type 1 diabetic human pregnancy. *Diabetes Metab. Res. Rev.* **24**, 294–300, <https://doi.org/10.1002/dmrr.793>
- 106 Sanches, J.C., Favaro, R.R., Barrence, F.C., Bevilacqua, E., Fortes, Z.B. and Zorn, T.M.T. (2017) Distinct effects of short- and long-term type 1 diabetes to the placental extracellular matrix and fetal development in mice. *Placenta* **53**, 1–7, <https://doi.org/10.1016/j.placenta.2017.03.005>
- 107 Favaro, R.R., Salgado, R.M., Covarrubias, A.C., Bruni, F., Lima, C., Fortes, Z.B. et al. (2013) Long-term type 1 diabetes impairs decidualization and extracellular matrix remodeling during early embryonic development in mice. *Placenta* **34**, 1128–1135, <https://doi.org/10.1016/j.placenta.2013.09.012>
- 108 Gauster, M., Majali-Martinez, A., Maninger, S., Gutsch, E., Greimel, P.H., Ivanisevic, M. et al. (2017) Maternal type 1 diabetes activates stress response in early placenta. *Placenta* **50**, 110–116, <https://doi.org/10.1016/j.placenta.2017.01.118>
- 109 Hastie, R. and Lappas, M. (2014) The effect of pre-existing maternal obesity and diabetes on placental mitochondrial content and electron transport chain activity. *Placenta* **35**, 673–683, <https://doi.org/10.1016/j.placenta.2014.06.368>
- 110 Araújo, J.R., Ramalho, C., Correia-Branco, A., Faria, A., Ferraz, T., Keating, E. et al. (2013) A parallel increase in placental oxidative stress and antioxidant defenses occurs in pre-gestational type 1 but not gestational diabetes. *Placenta* **34**, 1095–1098, <https://doi.org/10.1016/j.placenta.2013.09.001>
- 111 Beauharnais, C.C., Roberts, D.J. and Wexler, D.J. (2012) High rate of placental infarcts in type 2 compared with type 1 diabetes. *J. Clin. Endocrinol. Metab.* **97**, E1160–E1164, <https://doi.org/10.1210/jc.2011-3326>
- 112 Bisseling, T.M., Wouterse, A.C., Steegers, E.A., Elving, L., Russel, F.G. and Smits, P. (2003) Nitric oxide-mediated vascular tone in the fetal placental circulation of patients with type 1 diabetes mellitus. *Placenta* **24**, 974–978, [https://doi.org/10.1016/S0143-4004\(03\)00171-1](https://doi.org/10.1016/S0143-4004(03)00171-1)
- 113 Stanley, J.L., Cheung, C.C., Rueda-Clausen, C.F., Sankaralingam, S., Baker, P.N. and Davidge, S.T. (2011) Effect of gestational diabetes on maternal artery function. *Reproduct. Sci.* **18**, 342–352, <https://doi.org/10.1177/1933719110393029>
- 114 Morton, J.S., Care, A.S. and Davidge, S.T. (2017) Mechanisms of uterine artery dysfunction in pregnancy complications. *J. Cardiovasc. Pharmacol.* **69**, 343–359, <https://doi.org/10.1097/FJC.0000000000000468>
- 115 Razak, A.A., Leach, L. and Ralevic, V. (2018) Impaired vasoconstrictive responses to adenosine in chorionic vessels of human term placenta from pregnant women with pre-existing and gestational diabetes. *Diab. Vasc. Dis. Res.* **15**, 528–540, <https://doi.org/10.1177/1479164118790904>
- 116 Calles-Escandon, J. and Cipolla, M. (2001) Diabetes and endothelial dysfunction: a clinical perspective. *Endocr. Rev.* **22**, 36–52, <https://doi.org/10.1210/edrv.22.1.0417>
- 117 Ramsay, J.E., Simms, R.J., Ferrell, W.R., Crawford, L., Greer, I.A., Lumsden, M.A. et al. (2003) Enhancement of endothelial function by pregnancy. *Diabetes Care.* **26**, 475–479, <https://doi.org/10.2337/diacare.26.2.475>
- 118 DeFronzo, R.A., Ferrannini, E., Groop, L., Henry, R.R., Herman, W.H., Holst, J.J. et al. (2015) Type 2 diabetes mellitus. *Nat. Rev. Dis. Primers* **1**, 15019, <https://doi.org/10.1038/nrdp.2015.19>
- 119 Magliano, D.J., Sacre, J.W., Harding, J.L., Gregg, E.W., Zimmet, P.Z. and Shaw, J.E. (2020) Young-onset type 2 diabetes mellitus — implications for morbidity and mortality. *Nat. Rev. Endocrinol.* **16**, 321–331, <https://doi.org/10.1038/s41574-020-0334-z>
- 120 Temple, R. and Murphy, H. (2010) Type 2 diabetes in pregnancy - an increasing problem. *Best Pract. Res. Clin. Endocrinol. Metab.* **24**, 591–603, <https://doi.org/10.1016/j.beem.2010.05.011>

- 121 Castillo-Castrejón, M., Yamaguchi, K., Rodel, R.L., Erickson, K., Kramer, A., Hirsch, N.M. et al. (2021) Effect of type 2 diabetes mellitus on placental expression and activity of nutrient transporters and their association with birth weight and neonatal adiposity. *Mol. Cell. Endocrinol.* **532**, 111319, <https://doi.org/10.1016/j.mce.2021.111319>
- 122 Capobianco, E., Martínez, N., Fornes, D., Higa, R., Di Marco, I., Basualdo, M.N. et al. (2013) PPAR activation as a regulator of lipid metabolism, nitric oxide production and lipid peroxidation in the placenta from type 2 diabetic patients. *Mol. Cell. Endocrinol.* **377**, 7–15, <https://doi.org/10.1016/j.mce.2013.06.027>
- 123 Kapustin, R.V., Kopteyeva, E.V., Tral, T.G. and Tolibova, G.Kh. (2021) Placental morphology in different types of diabetes mellitus. *J. Obstet. women's Dis.* **70**, 13–26, <https://doi.org/10.17816/JOWD57149>
- 124 Napso, T., Lean, S.C., Lu, M., Mort, E.J., Desforges, M., Moghimi, A. et al. (2022) Diet-induced maternal obesity impacts fetoplacental growth and induces sex-specific alterations in placental morphology, mitochondrial bioenergetics, dynamics, lipid metabolism and oxidative stress in mice. *Acta Physiologica* **234** (4), e13795, <https://doi.org/10.1111/apha.13795>
- 125 Chen, K.H., Chen, L.R. and Lee, Y.H. (2012) The role of preterm placental calcification in high-risk pregnancy as a predictor of poor uteroplacental blood flow and adverse pregnancy outcome. *Ultrasound Med. Biol.* **38**, 1011–1018, <https://doi.org/10.1016/j.ultrasmedbio.2012.02.004>
- 126 Myatt, L. and Maloyan, A. (2016) Obesity and placental function. *Semin. Reprod. Med.* **34**, 042–049, <https://doi.org/10.1055/s-0035-1570027>
- 127 Jaiman, S., Romero, R., Pacora, P., Jung, E., Bhatti, G., Yeo, L. et al. (2020) Disorders of placental villous maturation in fetal death. *J. Perinat. Med.* **48** (4), 345–368, <https://doi.org/10.1515/jpm-2020-0030>
- 128 Browne, K., Park, B.Y., Goetzinger, K.R., Caughey, A.B. and Yao, R. (2021) The joint effects of obesity and pregestational diabetes on the risk of stillbirth. *J. Maternal-Fetal Neonatal Med.* **34**, 332–338, <https://doi.org/10.1080/14767058.2019.1607287>
- 129 Tarry-Adkins, J.L., Robinson, I.G., Pantaleão, L.C., Armstrong, J.L., Thackray, B.D., Holzner, L.M.W. et al. (2023) The metabolic response of human trophoblasts derived from term placentas to metformin. *Diabetologia* **66**, 2320–2331, <https://doi.org/10.1007/s00125-023-05996-3>
- 130 Tarry-Adkins, J.L., Robinson, I.G., Reynolds, R.M., Aye, I.L.M.H., Charnock-Jones, D.S., Jenkins, B. et al. (2022) Impact of metformin treatment on human placental energy production and oxidative stress. *Front. Cell Developmental Biol.* **10**, <https://doi.org/10.3389/fcell.2022.935403>
- 131 Asmussen, I. (1982) Ultrastructure of the villi and fetal capillaries of the placentas delivered by nonsmoking diabetic women (White Group D). *Acta Pathol. Microbiol. Scandinavica Series A :Pathology* **90A**, 95–101, <https://doi.org/10.1111/j.1699-0463.1982.tb00069.90A.x>
- 132 Boyd, P.A., Scott, A. and Keeling, J.W. (1986) Quantitative structural studies on placentas from pregnancies complicated by diabetes mellitus. *BJOG* **93**, 31–35, <https://doi.org/10.1111/j.1471-0528.1986.tb07809.x>
- 133 Fox, H. (1969) Pathology of the placenta in maternal diabetes mellitus. *Obstet. Gynecol.* **34**, 792–798
- 134 Fu, G., Brkić, J., Hayder, H. and Peng, C. (2013) MicroRNAs in human placental development and pregnancy complications. *Int. J. Mol. Sci.* **14**, 5519–5544, <https://doi.org/10.3390/ijms14035519>
- 135 Mouillet, J., Chu, T. and Sadovsky, Y. (2011) Expression patterns of placental microRNAs. *Birth Defects Res. A Clin. Mol. Teratol.* **91**, 737–743, <https://doi.org/10.1002/bdra.20782>
- 136 Bortolin-Cavaille, M.L., Dance, M., Weber, M. and Cavaille, J. (2009) C19MC microRNAs are processed from introns of large Pol-II, non-protein-coding transcripts. *Nucleic Acids Res.* **37**, 3464–3473, <https://doi.org/10.1093/nar/gkp205>
- 137 Taylor, A.S., Tinning, H., Ovchinnikov, V., Edge, J., Smith, W., Pullinger, A.L. et al. (2023) A burst of genomic innovation at the origin of placental mammals mediated embryo implantation. *Commun. Biol.* **6**, 459, <https://doi.org/10.1038/s42003-023-04809-y>
- 138 Malnou, E.C., Umlauf, D., Mouysset, M. and Cavaillé, J. (2019) Imprinted MicroRNA Gene clusters in the evolution, development, and functions of mammalian placenta. *Front. Genet.* **9**, <https://doi.org/10.3389/fgene.2018.00706>
- 139 O'Brien, J., Hayder, H., Zayed, Y. and Peng, C. (2018) Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. *Front. Endocrinol. (Lausanne)* **9**, <https://doi.org/10.3389/fendo.2018.00402>
- 140 Cai, Y., Yu, X., Hu, S. and Yu, J. (2009) A brief review on the mechanisms of miRNA regulation. *Genomics Proteomics Bioinform.* **7**, 147–154, [https://doi.org/10.1016/S1672-0229\(08\)60044-3](https://doi.org/10.1016/S1672-0229(08)60044-3)
- 141 Vishnoi, A. and Rani, S. (2017) MiRNA biogenesis and regulation of diseases: an overview. *Methods Mol. Biol.* **1509**, 1–10, [https://doi.org/10.1007/978-1-4939-6524-3\\_1](https://doi.org/10.1007/978-1-4939-6524-3_1)
- 142 Vasudevan, S. (2012) Posttranscriptional upregulation by MicroRNAs. *WIREs RNA* **3**, 311–330, <https://doi.org/10.1002/wrna.121>
- 143 Budak, H., Bulut, R., Kantar, M. and Alptekin, B. (2016) MicroRNA nomenclature and the need for a revised naming prescription. *Brief Funct. Genomics* **15** (1), 65–71, <https://doi.org/10.1093/bfgp/elv026>
- 144 Hume, L., Edge, J.C., Tinning, H., Wang, D., Taylor, A.S., Ovchinnikov, V. et al. (2023) MicroRNAs emerging coordinate with placental mammals alter pathways in endometrial epithelia important for endometrial function. *iScience* **26**, 106339, <https://doi.org/10.1016/j.isci.2023.106339>
- 145 Donker, R.B., Mouillet, J.F., Chu, T., Hubel, C.A., Stolz, D.B., Morelli, A.E. et al. (2012) The expression profile of C19MC microRNAs in primary human trophoblast cells and exosomes. *Mol. Hum. Reprod.* **18**, 417–424, <https://doi.org/10.1093/molehr/gas013>
- 146 Gong, S., Gaccioli, F., Dopierala, J., Sovio, U., Cook, E., Volders, P.J. et al. (2021) The RNA landscape of the human placenta in health and disease. *Nat. Commun.* **12**, 2639, <https://doi.org/10.1038/s41467-021-22695-y>
- 147 Paquette, A.G., Chu, T., Wu, X., Wang, K., Price, N.D. and Sadovsky, Y. (2018) Distinct communication patterns of trophoblastic miRNA among the maternal-placental-fetal compartments. *Placenta* **72–73**, 28–35, <https://doi.org/10.1016/j.placenta.2018.10.004>
- 148 Dini, P., Daels, P., Loux, S.C., Esteller-Vico, A., Carossino, M., Scoggin, K.E. et al. (2018) Kinetics of the chromosome 14 microRNA cluster ortholog and its potential role during placental development in the pregnant mare. *BMC Genomics* **19**, 954, <https://doi.org/10.1186/s12864-018-5341-2>
- 149 Inno, R., Kikas, T., Lillepea, K. and Laan, M. (2021) Coordinated expression landscape of the human placental miRNome and transcriptome. *Front. Cell Dev. Biol.* **9**, 697947, <https://doi.org/10.3389/fcell.2021.697947>

- 150 Smith, M.D., Pillman, K., Jankovic-Karasoulos, T., McAninch, D., Wan, Q., Bogias, K.J. et al. (2021) Large-scale transcriptome-wide profiling of microRNAs in human placenta and maternal plasma at early to mid gestation. *RNA Biol.* **18**, 507–520, <https://doi.org/10.1080/15476286.2021.1963105>
- 151 Addo, K.A., Palakodety, N., Hartwell, H.J., Tingare, A. and Fry, R.C. (2020) Placental microRNAs: responders to environmental chemicals and mediators of pathophysiology of the human placenta. *Toxicol. Rep.* **7**, 1046–1056, <https://doi.org/10.1016/j.toxrep.2020.08.002>
- 152 Poirier, C., Desgagné, V., Guérin, R. and Bouchard, L. (2017) MicroRNAs in pregnancy and gestational diabetes mellitus: emerging role in maternal metabolic regulation. *Curr. Diab. Rep.* **17**, 35, <https://doi.org/10.1007/s11892-017-0856-5>
- 153 Morales-Prieto, D.M., Ospina-Prieto, S., Chaiwangyen, W., Schoenleben, M. and Markert, U.R. (2013) Pregnancy-associated miRNA-clusters. *J. Reprod. Immunol.* **97**, 51–61, <https://doi.org/10.1016/j.jri.2012.11.001>
- 154 Tsamou, M., Nawrot, T.S., Carollo, R.M., Trippas, A.J., Lefebvre, W., Vanpoucke, C. et al. (2020) Prenatal particulate air pollution exposure and expression of the miR-17/92 cluster in cord blood: Findings from the ENVIRONAGE birth cohort. *Environ. Int.* **142**, 105860, <https://doi.org/10.1016/j.envint.2020.105860>
- 155 bao, C.D. and Wang, W. (2013) Human placental MicroRNAs and preeclampsia. *Biol. Reprod.* **88** (5), 1–11
- 156 Kumar, P., Luo, Y., Tudela, C., Alexander, J.M. and Mendelson, C.R. (2013) The c-Myc-regulated MicroRNA-17~92 (miR-17~92) and miR-106a~363 clusters target hCYP19A1 and hGCM1 to inhibit human trophoblast differentiation. *Mol. Cell. Biol.* **33**, 1782–1796, <https://doi.org/10.1128/MCB.01228-12>
- 157 Flowers, A.E., Gonzalez, T.L., Joshi, N.V., Eisman, L.E., Clark, E.L., Buttle, R.A. et al. (2021) Sex differences in microRNA expression in first and third trimester human placenta. *Biol. Reprod.* **106**, 551–567, <https://doi.org/10.1093/biolre/iaab221>
- 158 Quilang, R.C., Lui, S. and Forbes, K. (2022) miR-514a-3p: a novel SHP-2 regulatory miRNA that modulates human cytotrophoblast proliferation. *J. Mol. Endocrinol.* **68**, 99–110, <https://doi.org/10.1530/JME-21-0175>
- 159 Beards, F., Jones, L.E., Charnock, J., Forbes, K. and Harris, L.K. (2017) Placental homing peptide-microRNA inhibitor conjugates for targeted enhancement of intrinsic placental growth signaling. *Theranostics* **7**, 2940–2955, <https://doi.org/10.7150/thno.18845>
- 160 Cao, H., Hu, X., Zhang, Q., Wang, J., Li, J., Liu, B. et al. (2014) Upregulation of let-7a inhibits vascular smooth muscle cell proliferation in vitro and in vein graft intimal hyperplasia in rats. *J. Surg. Res.* **192**, 223–233, <https://doi.org/10.1016/j.jss.2014.05.045>
- 161 Johnson, C.D., Esquela-Kerscher, A., Stefani, G., Byrom, M., Kelnar, K., Ovcharenko, D. et al. (2007) The let-7 microRNA represses cell proliferation pathways in human cells. *Cancer Res.* **67**, 7713–7722, <https://doi.org/10.1158/0008-5472.CAN-07-1083>
- 162 Sachdeva, M. and Mo, Y.Y. (2010) miR-145-mediated suppression of cell growth, invasion and metastasis. *Am. J. Transl. Res.* **2**, 170–180
- 163 Zhang, L., Li, K., Tian, S., Wang, X.-Q., Li, J.-H., Dong, Y.-C. et al. (2021) Down-regulation of microRNA-30d-5p is associated with gestational diabetes mellitus by targeting RAB8A. *J. Diabetes Compl.* **35**, 107959, <https://doi.org/10.1016/j.jdiacomp.2021.107959>
- 164 Zhao, Q., Yuan, X., Zheng, L. and Xue, M. (2022) miR-30d-5p: a non-coding RNA with potential diagnostic, prognostic and therapeutic applications. *Front Cell Dev. Biol.* **10**, <https://doi.org/10.3389/fcell.2022.829435>
- 165 Wang, K., Liufu, S., Yu, Z., Xu, X., Ai, N., Li, X. et al. (2023) miR-100-5p regulates skeletal muscle myogenesis through the Trib2/mTOR/S6K signaling pathway. *Int. J. Mol. Sci.* **24**, 8906, <https://doi.org/10.3390/ijms24108906>
- 166 Cordes, K.R., Sheehy, N.T., White, M.P., Berry, E.C., Morton, S.U., Muth, A.N. et al. (2009) miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. *Nature* **460**, 705–710, <https://doi.org/10.1038/nature08195>
- 167 Yang, H., Hu, T., Hu, P., Qi, C. and Qian, L. (2021) miR-143-3p inhibits endometriotic stromal cell proliferation and invasion by inactivating autophagy in endometriosis. *Mol. Med. Rep.* **23**, 356, <https://doi.org/10.3892/mmr.2021.11995>
- 168 Jenike, A.E. and Halushka, M.K. (2021) miR-21: a non-specific biomarker of all maladies. *Biomark. Res.* **9**, 18, <https://doi.org/10.1186/s40364-021-00272-1>
- 169 Zhou, F., Sun, Y., Gao, Q. and Wang, H. (2020) microRNA-21 regulates the proliferation of placental cells via FOXM1 in preeclampsia. *Exp. Ther. Med.* **20** (3), 1871–1878, <https://doi.org/10.3892/etm.2020.8930>
- 170 Yamada, M., Kubo, H., Ota, C., Takahashi, T., Tando, Y., Suzuki, T. et al. (2013) The increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cells. *Respir. Res.* **14**, 95, <https://doi.org/10.1186/1465-9921-14-95>
- 171 Mouillet, J.F., Ouyang, Y., Coyne, C.B. and Sadovsky, Y. (2015) MicroRNAs in placental health and disease. *Am. J. Obstet. Gynecol.* **213**, S163–S172, <https://doi.org/10.1016/j.ajog.2015.05.057>
- 172 Chen, D., Xu, L., Wu, J., Liang, H., Liang, Y. and Liu, G. (2021) Downregulating miR-96-5p promotes proliferation, migration, and invasion, and inhibits apoptosis in human trophoblast cells via targeting DDAH1. *Reprod. Biol.* **21**, 100474, <https://doi.org/10.1016/j.repbio.2020.100474>
- 173 Tian, L., Cai, D., Zhuang, D., Wang, W., Wang, X., Bian, X. et al. (2020) miR-96-5p regulates proliferation, migration, and apoptosis of vascular smooth muscle cell induced by angiotensin II via targeting NFAT5. *J. Vasc. Res.* **57**, 86–96, <https://doi.org/10.1159/000505457>
- 174 Gu, Y., Bian, Y., Xu, X., Wang, X., Zuo, C., Meng, J. et al. (2016) Downregulation of miR-29a/b/c in placenta accreta inhibits apoptosis of implantation site intermediate trophoblast cells by targeting MCL1. *Placenta* **48**, 13–19, <https://doi.org/10.1016/j.placenta.2016.09.017>
- 175 Alizadeh, M., Safarzadeh, A., Beyranvand, F., Ahmadvand, F., Hajiasgharzadeh, K., Baghbanzadeh, A. et al. (2019) The potential role of miR-29 in health and cancer diagnosis, prognosis, and therapy. *J. Cell. Physiol.* **234**, 19280–19297, <https://doi.org/10.1002/jcp.28607>
- 176 Sun, F., Cai, H., Tan, L., Qin, D., Zhang, J., Hua, J. et al. (2022) Placenta-specific miR-125b overexpression leads to increased rates of pregnancy loss in mice. *Int. J. Mol. Sci.* **23**, 943, <https://doi.org/10.3390/ijms23020943>
- 177 Giroud, M., Pisani, D.F., Karbiener, M., Barquissau, V., Ghandour, R.A., Tews, D. et al. (2016) miR-125b affects mitochondrial biogenesis and impairs brite adipocyte formation and function. *Mol. Metab.* **5**, 615–625, <https://doi.org/10.1016/j.molmet.2016.06.005>
- 178 Maccani, M.A., Padbury, J.F. and Marsit, C.J. (2011) miR-16 and miR-21 expression in the placenta is associated with fetal growth. *PLoS ONE* **6**, e21210, <https://doi.org/10.1371/journal.pone.0021210>



- 179 Meng, M., Cheng, Y.K.Y., Wu, L., Chaemsaitong, P., Leung, M.B.W., Chim, S.S.C. et al. (2020) Whole genome miRNA profiling revealed miR-199a as potential placental pathogenesis of selective fetal growth restriction in monochorionic twin pregnancies. *Placenta* **92**, 44–53, <https://doi.org/10.1016/j.placenta.2020.02.002>
- 180 Lim, S., Deaver, J.W., Rosa-Caldwell, M.E., Lee, D.E., Morena da Silva, F., Cabrera, A.R. et al. (2022) Muscle miR-16 deletion results in impaired insulin sensitivity and contractile function in a sex-dependent manner. *Am. J. Physiol.-Endocrinol. Metab.* **322**, E278–E292, <https://doi.org/10.1152/ajpendo.00333.2021>
- 181 Wang, Y., Yang, L.Z., Yang, D.G., Zhang, Q.Y., Deng, Z.N., Wang, K. et al. (2020) MiR-21 antagomir improves insulin resistance and lipid metabolism disorder in streptozotocin-induced type 2 diabetes mellitus rats. *Ann. Palliat. Med.* **9**, 394–404, <https://doi.org/10.21037/apm.2020.02.28>
- 182 Ling, H.-Y., Hu, B., Hu, X.-B., Zhong, J., Feng, S.-D., Qin, L. et al. (2012) MiR-21 reverses high glucose and high insulin induced insulin resistance in 3T3-L1 adipocytes through targeting phosphatase and tensin homologue. *Exp. Clin. Endocrinol. Diab.* **120**, 553–559, <https://doi.org/10.1055/s-0032-1311644>
- 183 Yan, S.T., Li, C.L., Tian, H., Li, J., Pei, Y., Liu, Y. et al. (2014) MiR-199a is overexpressed in plasma of type 2 diabetes patients which contributes to type 2 diabetes by targeting GLUT4. *Mol. Cell. Biochem.* **397**, 45–51, <https://doi.org/10.1007/s11010-014-2170-8>
- 184 Baker, B.C., Lui, S., Lorne, I., Heazell, A.E.P., Forbes, K. and Jones, R.L. (2021) Sexually dimorphic patterns in maternal circulating microRNAs in pregnancies complicated by fetal growth restriction. *Biol. Sex Differ.* **12**, 61, <https://doi.org/10.1186/s13293-021-00405-z>
- 185 Crescitelli, R., Lässer, C., Szabó, T.G., Kittel, A., Eldh, M., Dianzani, I. et al. (2013) Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. *J. Extracell. Vesicles* **2**, <https://doi.org/10.3402/jev.v2i0.20677>
- 186 Zealy, R.W., Wrenn, S.P., Davila, S., Min, K. and Yoon, J. (2017) microRNA-binding proteins: specificity and function. *WIREs RNA* **8**, e1414, <https://doi.org/10.1002/wrna.1414>
- 187 Welsh, J.A., Goberdhan, D.C.I., O’Driscoll, L., Buzas, E.I., Blenkiron, C., Bussolati, B. et al. (2024) Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. *J. Extracell. Vesicles* **13**, e12404, <https://doi.org/10.1002/jev2.12404>
- 188 Jayabalan, N., Lai, A., Ormazabal, V., Adam, S., Guanzon, D., Palma, C. et al. (2019) Adipose tissue exosomal proteomic profile reveals a role on placenta glucose metabolism in gestational diabetes mellitus. *J. Clin. Endocrinol. Metab.* **104**, 1735–1752, <https://doi.org/10.1210/jc.2018-01599>
- 189 Doyle, L. and Wang, M. (2019) Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. *Cells* **8**, 727, <https://doi.org/10.3390/cells8070727>
- 190 Mulcahy, L.A., Pink, R.C. and Carter, D.R.F. (2014) Routes and mechanisms of extracellular vesicle uptake. *J. Extracell. Vesicles* **3**, 24641, <https://doi.org/10.3402/jev.v3.24641>
- 191 Germain, S.J., Sacks, G.P., Soorana, S.R., Sargent, I.L. and Redman, C.W. (2007) Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. *J. Immunol.* **178**, 5949–5956, <https://doi.org/10.4049/jimmunol.178.9.5949>
- 192 Holder, B.S., Tower, C.L., Forbes, K., Mulla, M.J., Aplin, J.D. and Abrahams, V.M. (2012) Immune cell activation by trophoblast-derived microvesicles is mediated by syncytin 1. *Immunology* **136**, 184–191, <https://doi.org/10.1111/j.1365-2567.2012.03568.x>
- 193 Mincheva-Nilsson, L. and Baranov, V. (2014) Placenta-derived exosomes and syncytiotrophoblast microparticles and their role in human reproduction: immune modulation for pregnancy success. *Am. J. Reprod. Immunol.* **72**, 440–457, <https://doi.org/10.1111/aji.12311>
- 194 Tong, M., Chen, Q., James, J.L., Wise, M.R., Stone, P.R. and Chamley, L.W. (2017) In vivo targets of human placental micro-vesicles vary with exposure time and pregnancy. *Reproduction* **153**, 835–845, <https://doi.org/10.1530/REP-16-0615>
- 195 Adam, S., Elfeky, O., Kinhal, V., Dutta, S., Lai, A., Jayabalan, N. et al. (2017) Review: fetal-maternal communication via extracellular vesicles - implications for complications of pregnancies. *Placenta* **54**, 83–88, <https://doi.org/10.1016/j.placenta.2016.12.001>
- 196 Zierden, H.C., Marx-Rattner, R., Rock, K.D., Montgomery, K.R., Anastasiadis, P., Folts, L. et al. (2023) Extracellular vesicles are dynamic regulators of maternal glucose homeostasis during pregnancy. *Sci. Rep.* **13**, 4568, <https://doi.org/10.1038/s41598-023-31425-x>
- 197 Chang, G., Mouillet, J., Mishima, T., Chu, T., Sadovsky, E., Coyne, C.B. et al. (2017) Expression and trafficking of placental microRNAs at the fetomaternal interface. *FASEB J.* **31**, 2760–2770, <https://doi.org/10.1096/fj.201601146R>
- 198 Morales-Prieto, D.M., Favaro, R.R. and Markert, U.R. (2020) Placental miRNAs in fetomaternal communication mediated by extracellular vesicles. *Placenta* **102**, 27–33, <https://doi.org/10.1016/j.placenta.2020.07.001>
- 199 Herrera-Van Oostdam, A., Toro-Ortiz, J., López, J., Noyola, D., García-López, D., Durán-Figueroa, N. et al. (2020) Placental exosomes isolated from urine of patients with gestational diabetes exhibit a differential profile expression of microRNAs across gestation. *Int. J. Mol. Med.* **46**, 546–560, <https://doi.org/10.3892/ijmm.2020.4626>
- 200 Gillet, V., Ouellet, A., Stepanov, Y., Rodosthenous, R.S., Croft, E.K., Brennan, K. et al. (2019) miRNA profiles in extracellular vesicles from serum early in pregnancies complicated by gestational diabetes mellitus. *J. Clin. Endocrinol. Metab.* **104**, 5157–5169, <https://doi.org/10.1210/jc.2018-02693>
- 201 Delorme-Axford, E., Donker, R.B., Mouillet, J.F., Chu, T., Bayer, A., Ouyang, Y. et al. (2013) Human placental trophoblasts confer viral resistance to recipient cells. *Proc. Natl. Acad. Sci.* **110**, 12048–12053, <https://doi.org/10.1073/pnas.1304718110>
- 202 Kovács, Á.F., Fekete, N., Turiák, L., Ács, A., Köhidai, L., Buzás, E.I. et al. (2019) Unravelling the role of trophoblastic-derived extracellular vesicles in regulatory T cell differentiation. *Int. J. Mol. Sci.* **20**, 3457, <https://doi.org/10.3390/ijms20143457>
- 203 Ospina-Prieto, S., Chaiwangyen, W., Herrmann, J., Groten, T., Schleussner, E., Markert, U.R. et al. (2016) MicroRNA-141 is upregulated in preeclamptic placentae and regulates trophoblast invasion and intercellular communication. *Transl. Res.* **172**, 61–72, <https://doi.org/10.1016/j.trsl.2016.02.012>
- 204 Holder, B., Jones, T., Sancho Shimizu, V., Rice, T.F., Donaldson, B., Bouqueau, M. et al. (2016) Macrophage exosomes induce placental inflammatory cytokines: a novel mode of maternal-placental messaging. *Traffic* **17**, 168–178, <https://doi.org/10.1111/tra.12352>
- 205 Quilang, R., Godinho, E., Timms, K., Scott, E.M. and Forbes, K. (2022) ODP434 maternally-derived pancreatic extracellular vesicle encompassed miRNAs influence placental development in pregnancies complicated by gestational diabetes. *J. Endocr. Soc.* **6**, A671–A672, <https://doi.org/10.1210/jendso/bvac150.1389>



- 206 Kennedy, M.G. (2022) *Circulating miRNAs as key regulators of placental vascular dysfunction and altered fetal growth in pregnancies complicated by diabetes*, University of Leeds, PhD thesis
- 207 Timms, K., Holder, B., Day, A., Mclaughlin, J., Forbes, K.A. and Westwood, M. (2022) Watermelon-derived extracellular vesicles influence human ex vivo placental cell behavior by altering intestinal secretions. *Mol. Nutr. Food Res.* **66** (19), 2200013, <https://doi.org/10.1002/mnfr.202200013>
- 208 Fuso, A., Raia, T., Orticello, M. and Lucarelli, M. (2020) The complex interplay between DNA methylation and miRNAs in gene expression regulation. *Biochimie* **173**, 12–16, <https://doi.org/10.1016/j.biochi.2020.02.006>
- 209 Shah, K.B., Chernausek, S.D., Teague, A.M., Bard, D.E. and Tryggstad, J.B. (2021) Maternal diabetes alters microRNA expression in fetal exosomes, human umbilical vein endothelial cells and placenta. *Pediatr. Res.* **89**, 1157–1163, <https://doi.org/10.1038/s41390-020-1060-x>
- 210 Sun, D.G., Tian, S., Zhang, L., Hu, Y., Guan, C.Y., Ma, X. et al. (2020) The miRNA-29b is downregulated in placenta during gestational diabetes mellitus and may alter placenta development by regulating trophoblast migration and invasion through a HIF3A-dependent mechanism. *Front Endocrinol. (Lausanne)* **11**, <https://doi.org/10.3389/fendo.2020.00169>
- 211 Muralimanoharan, S., Maloyan, A. and Myatt, L. (2016) Mitochondrial function and glucose metabolism in the placenta with gestational diabetes mellitus: role of *miR-143*. *Clin. Sci.* **130**, 931–941, <https://doi.org/10.1042/CS20160076>
- 212 Guan, C.Y., Tian, S., Cao, J.L., Wang, X.Q., Ma, X. and Xia, H.F. (2020) Down-regulated miR-21 in gestational diabetes mellitus placenta induces PPAR- $\alpha$  to inhibit cell proliferation and infiltration. *Diab. Metab. Syndr. Obes.* **13**, 3009–3034, <https://doi.org/10.2147/DMSO.S253920>
- 213 Zhao, C., Zhang, T., Shi, Z., Ding, H. and Ling, X. (2014) MicroRNA-518d regulates PPAR $\alpha$  protein expression in the placentas of females with gestational diabetes mellitus. *Mol. Med. Rep.* **9**, 2085–2090, <https://doi.org/10.3892/mmr.2014.2058>
- 214 Cao, J.L., Zhang, L., Li, J., Tian, S., Lv, X.D., Wang, X.Q. et al. (2016) Up-regulation of miR-98 and unraveling regulatory mechanisms in gestational diabetes mellitus. *Sci. Rep.* **6**, 32268, <https://doi.org/10.1038/srep32268>
- 215 Ding, R., Guo, F., Zhang, Y., Liu, X.M., Xiang, Y.Q., Zhang, C. et al. (2018) Integrated transcriptome sequencing analysis reveals role of miR-138-5p/TBL1X in placenta from gestational diabetes mellitus. *Cell. Physiol. Biochem.* **51**, 630–646, <https://doi.org/10.1159/000495319>
- 216 Song, T.R., Su, G.D., Chi, Y.L., Wu, T., Xu, Y. and Chen, C.C. (2021) Dysregulated miRNAs contribute to altered placental glucose metabolism in patients with gestational diabetes via targeting GLUT1 and HK2. *Placenta* **105**, 14–22, <https://doi.org/10.1016/j.placenta.2021.01.015>
- 217 Zhao, C., Zhao, C. and Zhao, H. (2020) Defective insulin receptor signaling in patients with gestational diabetes is related to dysregulated miR-140 which can be improved by naringenin. *Int. J. Biochem. Cell Biol.* **128**, 105824, <https://doi.org/10.1016/j.biocel.2020.105824>
- 218 Zhou, X., Xiang, C. and Zheng, X. (2019) miR-132 serves as a diagnostic biomarker in gestational diabetes mellitus and its regulatory effect on trophoblast cell viability. *Diagn. Pathol.* **14**, 119, <https://doi.org/10.1186/s13000-019-0899-9>
- 219 Du, R., Wu, N., Bai, Y., Tang, L. and Li, L. (2022) circMAP3K4 regulates insulin resistance in trophoblast cells during gestational diabetes mellitus by modulating the miR-6795-5p/PTPN1 axis. *J. Transl. Med.* **20**, 180, <https://doi.org/10.1186/s12967-022-03386-8>
- 220 Zhang, C., Wang, L., Chen, J., Song, F. and Guo, Y. (2020) Differential expression of miR-136 in gestational diabetes mellitus mediates the high-glucose-induced trophoblast cell injury through targeting E2F1. *Int. J. Genomics* **2020**, 1–10, <https://doi.org/10.1155/2020/3645371>
- 221 Li, Y. and Zhuang, J. (2020) miR-345-3p serves a protective role during gestational diabetes mellitus by targeting BAK1. *Exp. Ther. Med.* **20**, 1–1, <https://doi.org/10.3892/etm.2020.9434>
- 222 Tan, L., Peng, Q.J. and Chen, L.C. (2016) miR-95, -548am and -1246 expression in placenta tissue of gestational diabetes mellitus as well as their relationship with adipocytokines and glucose transporters. *J. Hainan Med. University* **22**, 5–8
- 223 Li, W., Yuan, X., He, X., Yang, L., Wu, Y., Deng, X. et al. (2022) The downregulation of miR-22 and miR-372 may contribute to gestational diabetes mellitus through regulating glucose metabolism via the PI3K/ AKT/GLUT4 pathway. *J. Clin. Lab. Anal.* **36**, e24557, <https://doi.org/10.1002/jcla.24557>
- 224 Liu, L., Zhang, J. and Liu, Y. (2021) MicroRNA-1323 serves as a biomarker in gestational diabetes mellitus and aggravates high glucose-induced inhibition of trophoblast cell viability by suppressing TP53INP1. *Exp. Ther. Med.* **21**, 230, <https://doi.org/10.3892/etm.2021.9661>
- 225 Wang, P., Wang, Z., Liu, G., Jin, C., Zhang, Q., Man, S. et al. (2019) miR-657 promotes macrophage polarization toward M1 by targeting FAM46C in gestational diabetes mellitus. *Mediators Inflamm.* **2019**, 1–9, <https://doi.org/10.1155/2019/4851214>
- 226 Guan, C.Y., Cao, J.L., Zhang, L., Wang, X.Q., Ma, X. and Xia, H.F. (2022) miR-199a is upregulated in GDM targeting the MeCP2-Trpc3 pathway. *Front Endocrinol. (Lausanne)* **13**, <https://doi.org/10.3389/fendo.2022.917386>
- 227 Zheng, H., Yu, Z., Wang, H., Liu, H. and Chen, X. (2022) MicroRNA-195-5p facilitates endothelial dysfunction by inhibiting vascular endothelial growth factor A in gestational diabetes mellitus. *Reprod. Biol.* **22**, 100605, <https://doi.org/10.1016/j.repbio.2022.100605>
- 228 Wang, P., Ma, Z., Wang, Z., Wang, X., Zhao, G. and Wang, Z. (2021) MiR-6869-5p induces M2 polarization by regulating PTPRO in gestational diabetes mellitus. *Mediators Inflamm.* **2021**, 1–8, <https://doi.org/10.1155/2021/6696636>
- 229 Floris, I., Descamps, B., Vardeu, A., Mitić, T., Posadino, A.M., Shantikumar, S. et al. (2015) Gestational diabetes mellitus impairs fetal endothelial cell functions through a mechanism involving MicroRNA-101 and histone methyltransferase enhancer of zester homolog-2. *Arterioscler. Thromb. Vasc. Biol.* **35**, 664–674, <https://doi.org/10.1161/ATVBAHA.114.304730>
- 230 Ke, W., Chen, Y., Zheng, L., Zhang, Y., Wu, Y. and Li, L. (2022) miR-134-5p promotes inflammation and apoptosis of trophoblast cells via regulating FOXP2 transcription in gestational diabetes mellitus. *Bioengineered* **13**, 319–330, <https://doi.org/10.1080/21655979.2021.2001219>
- 231 Peng, H.Y., Li, H.P. and Li, M.Q. (2018) High glucose induces dysfunction of human umbilical vein endothelial cells by upregulating miR-137 in gestational diabetes mellitus. *Microvasc. Res.* **118**, 90–100, <https://doi.org/10.1016/j.mvr.2018.03.002>
- 232 Zhang, M. and Zhu, X. (2018) miR-9-5p plays an important role in gestational diabetes mellitus (GDM) progression by targeting HK-2. *Int. J. Clin. Exp. Med.* **11**, 6694–6701
- 233 Liao, X., Zhou, Z. and Zhang, X. (2020) Effects of miR-195-5p on cell proliferation and apoptosis in gestational diabetes mellitus via targeting EZH2. *Mol. Med. Rep.* **22**, 803–809, <https://doi.org/10.3892/mmr.2020.11142>
- 234 Yu, X., Liu, Z., Fang, J. and Qi, H. (2021) miR-96-5p: a potential diagnostic marker for gestational diabetes mellitus. *Medicine (Baltimore)* **100**, e25808, <https://doi.org/10.1097/MD.00000000000025808>

- 235 Ji, Y., Zhang, W., Yang, J. and Li, C. (2020) MiR-193b inhibits autophagy and apoptosis by targeting IGFBP5 in high glucose-induced trophoblasts. *Placenta* **101**, 185–193, <https://doi.org/10.1016/j.placenta.2020.09.015>
- 236 Song, F., Cai, A., Ye, Q., Chen, X., Lin, L. and Hao, X. (2021) MiR-34b-3p impaired HUVECs viability and migration via targeting PDK1 in an in vitro model of gestational diabetes mellitus. *Biochem. Genet.* **59**, 1381–1395, <https://doi.org/10.1007/s10528-021-10064-9>
- 237 Wang, S., Wei, D., Sun, X., Li, Y., Li, D. and Chen, B. (2021) MiR-190b impedes pancreatic  $\beta$  cell proliferation and insulin secretion by targeting NKX6-1 and may associate to gestational diabetes mellitus. *J. Recept. Signal Transduct.* **41**, 349–356, <https://doi.org/10.1080/10799893.2020.1810705>
- 238 Xu, K., Bian, D., Hao, L., Huang, F., Xu, M., Qin, J. et al. (2017) microRNA-503 contribute to pancreatic beta cell dysfunction by targeting the mTOR pathway in gestational diabetes mellitus. *EXCLI J.* **16**, 1177–1187
- 239 Zhang, L., Zhang, T., Sun, D., Cheng, G., Ren, H., Hong, H. et al. (2021) Diagnostic value of dysregulated microribonucleic acids in the placenta and circulating exosomes in gestational diabetes mellitus. *J. Diab. Investig.* **12**, 1490–1500, <https://doi.org/10.1111/jdi.13493>
- 240 Li, L., Wang, S., Li, H., Wan, J., Zhou, Q., Zhou, Y. et al. (2018) microRNA-96 protects pancreatic  $\beta$ -cell function by targeting PAK1 in gestational diabetes mellitus. *Biofactors* **44**, 539–547, <https://doi.org/10.1002/biof.1461>
- 241 Chen, X., Yang, F., Zhang, T., Wang, W., Xi, W., Li, Y. et al. (2019) MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma. *J. Exp. Clin. Cancer Res.* **38**, 99, <https://doi.org/10.1186/s13046-019-1078-2>
- 242 Shi, Z., Zhao, C., Guo, X., Ding, H., Cui, Y., Shen, R. et al. (2014) Differential expression of MicroRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals mir-222 as a regulator of ER $\alpha$  expression in estrogen-induced insulin resistance. *Endocrinology* **155**, 1982–1990, <https://doi.org/10.1210/en.2013-2046>
- 243 Lee, A., Papangelis, I., Park, Y., Jeong, H.-n., Choi, J., Kang, H. et al. (2017) A PPAR $\gamma$ -dependent miR-424/503-CD40 axis regulates inflammation mediated angiogenesis. *Sci. Rep.* **7**, 2528, <https://doi.org/10.1038/s41598-017-02852-4>
- 244 Caporali, A., Meloni, M., Völlenkle, C., Bonci, D., Sala-Newby, G.B., Addis, R. et al. (2011) Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. *Circulation* **123**, 282–291, <https://doi.org/10.1161/CIRCULATIONAHA.110.952325>
- 245 Hou, L.J., Han, J.J. and Liu, Y. (2018) Up-regulation of microRNA-503 by high glucose reduces the migration and proliferation but promotes the apoptosis of human umbilical vein endothelial cells by inhibiting the expression of insulin-like growth factor-1 receptor. *Eur. Rev. Med. Pharmacol. Sci.* **22**, 3515–3523
- 246 Joshi, N.P., Mane, A.R., Sahay, A.S., Sundrani, D.P., Joshi, S.R. and Yajnik, C.S. (2022) Role of placental glucose transporters in determining fetal growth. *Reproduct. Sci.* **29**, 2744–2759, <https://doi.org/10.1007/s43032-021-00699-9>
- 247 Chassen, S. and Jansson, T. (2020) Complex, coordinated and highly regulated changes in placental signaling and nutrient transport capacity in IUGR. *Biochim. Biophys. Acta* **1866**, 165373, <https://doi.org/10.1016/j.bbadis.2018.12.024>
- 248 Sferruzzi-Perri, A.N., Lopez-Tello, J. and Salazar-Petres, E. (2023) Placental adaptations supporting fetal growth during normal and adverse gestational environments. *Exp. Physiol.* **108**, 371–397, <https://doi.org/10.1113/EP090442>
- 249 Chappell, J., Aughwane, R., Clark, A.R., Ourselin, S., David, A.L. and Melbourne, A. (2023) A review of feto-placental vasculature flow modelling. *Placenta* **142**, 56–63, <https://doi.org/10.1016/j.placenta.2023.08.068>
- 250 Goldstein, J.A., Gallagher, K., Beck, C., Kumar, R. and Gernand, A.D. (2020) Maternal-fetal inflammation in the placenta and the developmental origins of health and disease. *Front Immunol.* **11**, <https://doi.org/10.3389/fimmu.2020.531543>
- 251 Strutz, J., Cvitic, S., Hackl, H., Kashofer, K., Appel, H.M., Thüringer, A. et al. (2018) Gestational diabetes alters microRNA signatures in human feto-placental endothelial cells depending on fetal sex. *Clin. Sci.* **132**, 2437–2449, <https://doi.org/10.1042/CS20180825>
- 252 Forbes, K., Farrokhnia, F., Aplin, J.D. and Westwood, M. (2012) Dicer-dependent miRNAs provide an endogenous restraint on cytotrophoblast proliferation. *Placenta* **33**, 581–585, <https://doi.org/10.1016/j.placenta.2012.03.006>
- 253 Rahimi, G., Jafari, N., Khodabakhsh, M., Shirzad, Z. and Dogaeheh, H.P. (2015) Upregulation of microRNA processing enzymes drosha and dicer in gestational diabetes mellitus. *Gynecol. Endocrinol.* **31**, 156–159, <https://doi.org/10.3109/09513590.2014.969700>
- 254 Yang, W., Lu, Z., Zhi, Z., Liu, L., Deng, L., Jiang, X. et al. (2019) Increased miRNA-518b inhibits trophoblast migration and angiogenesis by targeting EGR1 in early embryonic arrest. *Biol. Reprod.* **101**, 664–674, <https://doi.org/10.1093/biolre/iox109>
- 255 Wu, H.M., Lo, T.C., Tsai, C.L., Chen, L.H., Huang, H.Y., Wang, H.S. et al. (2022) Extracellular vesicle-associated microRNA-138-5p regulates embryo implantation and early pregnancy by adjusting GPR124. *Pharmaceutics* **14**, 1172, <https://doi.org/10.3390/pharmaceutics14061172>
- 256 Ni, H., Wang, X., Qu, H., Gao, X. and Yu, X. (2021) MiR-95-5p involves in the migration and invasion of trophoblast cells by targeting low density lipoprotein receptor-related protein 6. *J. Obstet. Gynaecol. Res.* **47**, 184–197, <https://doi.org/10.1111/jog.14451>
- 257 Zhou, D., Xu, X., Liu, Y., Liu, H., Cheng, X., Gu, Y. et al. (2022) MiR-195-5p facilitates the proliferation, migration, and invasion of human trophoblast cells by targeting FGF2. *J. Obstet. Gynaecol. Res.* **48**, 2122–2133, <https://doi.org/10.1111/jog.15298>
- 258 Laurini, R., Visser, G., Vanballegoie, E. and Schoots, C. (1987) Morphological findings in placentae of insulin-dependent diabetic patients treated with continuous subcutaneous insulin infusion (CSII). *Placenta* **8**, 153–165, [https://doi.org/10.1016/0143-4004\(87\)90018-X](https://doi.org/10.1016/0143-4004(87)90018-X)
- 259 Luo, M., Tan, X., Mu, L., Luo, Y., Li, R., Deng, X. et al. (2017) MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway. *Sci. Rep.* **7**, 43427, <https://doi.org/10.1038/srep43427>
- 260 Ding, Y., Yuan, X., Gu, W. and Lu, L. (2019) Treatment with metformin prevents pre-eclampsia by suppressing migration of trophoblast cells via modulating the signaling pathway of UCA1/miR-204/MMP-9. *Biochem. Biophys. Res. Commun.* **520**, 115–121, <https://doi.org/10.1016/j.bbrc.2019.09.099>
- 261 Demiroş İ, H., Ertural, D.Y., Balci, Ş., Çinkir, Ü., Sezer, K., Tamer, L. et al. (2018) Profiles of circulating miRNAs following metformin treatment in patients with Type 2 diabetes. *J. Med. Biochem.* **37**, 499–506, <https://doi.org/10.2478/jomb-2018-0009>

- 262 Ortega, F.J., Mercader, J.M., Moreno-Navarrete, J.M., Rovira, O., Guerra, E., Esteve, E. et al. (2014) Profiling of circulating microRNAs reveals common microRNAs linked to Type 2 diabetes that change with insulin sensitization. *Diabetes Care*, **37**, 1375–1383, <https://doi.org/10.2337/dc13-1847>
- 263 Ghai, V., Kim, T.K., Etheridge, A., Nielsen, T., Hansen, T., Pedersen, O. et al. (2019) Extracellular vesicle encapsulated microRNAs in patients with Type 2 diabetes are affected by metformin treatment. *J. Clin. Med.* **8**, <https://doi.org/10.3390/jcm8050617>
- 264 Adaikalakoteswari, A., Vatish, M., Alam, M.T., Ott, S., Kumar, S. and Saravanan, P. (2017) Low vitamin B12 in Pregnancy is associated with adipose-derived circulating miRs targeting PPAR $\gamma$  and insulin resistance. *J. Clin. Endocrinol. Metab.* **102**, 4200–4209, <https://doi.org/10.1210/je.2017-01155>
- 265 Baker, B.C., Mackie, F.L., Lean, S.C., Greenwood, S.L., Heazell, A.E.P., Forbes, K. et al. (2017) Placental dysfunction is associated with altered microRNA expression in pregnant women with low folate status. *Mol. Nutr. Food Res.* **61**, <https://doi.org/10.1002/mnfr.201600646>
- 266 Shah, T., Mishra, S., More, A., Otv, S., Apte, K. and Joshi, K. (2017) Combination of vitamin B12 active forms improved fetal growth in Wistar rats through up-regulation of placental miR-16 and miR-21 levels. *Life Sci.* **191**, 97–103, <https://doi.org/10.1016/j.lfs.2017.10.017>
- 267 Masete, M., Dias, S., Malaza, N., Adam, S. and Pheiffer, C. (2022) A big role for microRNAs in gestational diabetes mellitus. *Front Endocrinol. (Lausanne)* **13**, <https://doi.org/10.3389/fendo.2022.892587>
- 268 Quilang, R., Byford, A., Scott, E.M. and Forbes, K. (2022) Maternally derived pancreatic extracellular vesicle miR-375 contributes to large-for-gestational-age infants in pregnancies complicated by gestational diabetes. *Endocrine Abstracts* **86**, OC3, 4, <https://doi.org/10.1530/endoabs.86.OC3.4>
- 269 Nair, S. and Salomon, C. (2020) Extracellular vesicles as critical mediators of maternal-fetal communication during pregnancy and their potential role in maternal metabolism. *Placenta* **98**, 60–68, <https://doi.org/10.1016/j.placenta.2020.06.011>
- 270 Nair, S., Guanzon, D., Jayabalan, N., Lai, A., Scholz-Romero, K., Kalita de Croft, P. et al. (2021) Extracellular vesicle-associated miRNAs are an adaptive response to gestational diabetes mellitus. *J. Transl. Med.* **19**, 360, <https://doi.org/10.1186/s12967-021-02999-9>
- 271 Salomon, C., Scholz-Romero, K., Sarker, S., Sweeney, E., Kobayashi, M., Correa, P. et al. (2016) Gestational diabetes mellitus is associated with changes in the concentration and bioactivity of placenta-derived exosomes in maternal circulation across gestation. *Diabetes* **65**, 598–609, <https://doi.org/10.2337/db15-0966>
- 272 Dinesen, S., El-Faitarouni, A. and Dalgaard, L.T. (2023) Circulating microRNAs associated with gestational diabetes mellitus: useful biomarkers? *J. Endocrinol.* **256**, e220170, <https://doi.org/10.1530/JOE-22-0170>
- 273 Zhang, Q., Ye, X., Xu, X. and Yan, J. (2023) Placenta-derived exosomal miR-135a-5p promotes gestational diabetes mellitus pathogenesis by activating PI3K/AKT signalling pathway via SIRT1. *J. Cell. Mol. Med.* **27**, 3729–3743, <https://doi.org/10.1111/jcmm.17941>
- 274 Gao, Z., Wang, N. and Liu, X. (2022) Human placenta mesenchymal stem cell-derived exosome shuttling microRNA-130b-3p from gestational diabetes mellitus patients targets ICAM-1 and perturbs human umbilical vein endothelial cell angiogenesis. *Acta Diabetol.* **59**, 1091–1107, <https://doi.org/10.1007/s00592-022-01910-2>
- 275 Zhang, L., Wu, Q., Zhu, S., Tang, Y., Chen, Y., Chen, D. et al. (2022) Chemerin-induced down-regulation of placenta-derived exosomal miR-140-3p and miR-574-3p promotes umbilical vein endothelial cells proliferation, migration, and tube formation in gestational diabetes mellitus. *Cells* **11**, 3457, <https://doi.org/10.3390/cells11213457>
- 276 Nair, S., Jayabalan, N., Guanzon, D., Palma, C., Scholz-Romero, K., Elfeky, O. et al. (2018) Human placental exosomes in gestational diabetes mellitus carry a specific set of miRNAs associated with skeletal muscle insulin sensitivity. *Clin. Sci.* **132**, 2451–2467, <https://doi.org/10.1042/CS20180487>
- 277 Elfeky, O., Longo, S., Lai, A., Rice, G.E. and Salomon, C. (2017) Influence of maternal BMI on the exosomal profile during gestation and their role on maternal systemic inflammation. *Placenta* **50**, 60–69, <https://doi.org/10.1016/j.placenta.2016.12.020>
- 278 Sun, X., Lin, J., Zhang, Y., Kang, S., Belkin, N., Wara, A.K. et al. (2016) MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue. *Circ. Res.* **118**, 810–821, <https://doi.org/10.1161/CIRCRESAHA.115.308166>
- 279 Zhang, Z., Xu, Q., Chen, Y., Sui, L., Jiang, L., Shen, Q. et al. (2021) The possible role of visceral fat in early pregnancy as a predictor of gestational diabetes mellitus by regulating adipose-derived exosomes miRNA-148 family: protocol for a nested case-control study in a cohort study. *BMC Pregnancy Childbirth* **21**, 262, <https://doi.org/10.1186/s12884-021-03737-1>
- 280 Jiang, H., Wu, W., Zhang, M., Li, J., Peng, Y., Miao, T.-T. et al. (2014) Aberrant upregulation of miR-21 in placental tissues of macrosomia. *J. Perinatol.* **34**, 658–663, <https://doi.org/10.1038/jp.2014.58>
- 281 ZHANG JT, C.A.I.Q.Y., Ji, S.S., ZHANG, H.X., WANG YH, Y.A.N.H.T. et al. (2016) Decreased miR-143 and increased miR-21 placental expression levels are associated with macrosomia. *Mol. Med. Rep.* **13**, 3273–3280, <https://doi.org/10.3892/mmr.2016.4892>
- 282 Guo, D., Jiang, H., Chen, Y., Yang, J., Fu, Z., Li, J. et al. (2018) Elevated microRNA-141-3p in placenta of non-diabetic macrosomia regulate trophoblast proliferation. *EBioMedicine* **38**, 154–161, <https://doi.org/10.1016/j.ebiom.2018.11.002>
- 283 Li, J., Song, L., Zhou, L., Wu, J., Sheng, C., Chen, H. et al. (2015) A microRNA signature in gestational diabetes mellitus associated with risk of macrosomia. *Cell. Physiol. Biochem.* **37**, 243–252, <https://doi.org/10.1159/000430349>
- 284 Marei, E. and Gabr Youssef, H. (2021) Evaluation of microRNA-16 and microRNA-221 in serum and placenta in gestational diabetes mellitus: correlation with macrosomia. *Egyptian J. Radiation Sci. Appl.* **33** (2), 107–118, <https://doi.org/10.21608/ejrsa.2021.53195.1110>
- 285 Calimlioglu, B., Karagoz, K., Sevimgoglu, T., Kilic, E., Gov, E. and Arga, K.Y. (2015) Tissue-specific molecular biomarker signatures of type 2 diabetes: an integrative analysis of transcriptomics and protein-protein interaction data. *OMICS* **19**, 563–573, <https://doi.org/10.1089/omi.2015.0088>
- 286 Guiyu, S., Quan, N., Ruochen, W., Dan, W., Bingnan, C., Yuanyua, L. et al. (2022) LncRNA-SNX17 promotes HTR-8/SVneo proliferation and invasion through miR-517a/IGF-1 in the placenta of diabetic macrosomia. *Reproduct. Sci.* **29**, 596–605, <https://doi.org/10.1007/s43032-021-00687-z>
- 287 Yuan, L., Shi, R., Zhao, L., Cai, W., Zhou, X., Zhang, Y. et al. (2017) Maternal exosomes contribute to the fetal cardiac development deficiency in mother with pre-existing diabetes: a fetal echocardiography based animal study. *Ultrasound Med. Biol.* **43**, S10, <https://doi.org/10.1016/j.ultrasmedbio.2017.08.968>



- 288 Shi, R., Zhao, L., Cai, W., Wei, M., Zhou, X., Yang, G. et al. (2017) Maternal exosomes in diabetes contribute to the cardiac development deficiency. *Biochem. Biophys. Res. Commun.* **483**, 602–608, <https://doi.org/10.1016/j.bbrc.2016.12.097>
- 289 Liu, Y., Wang, Y., Wang, C., Shi, R., Zhou, X., Li, Z. et al. (2021) Maternal obesity increases the risk of fetal cardiac dysfunction via visceral adipose tissue derived exosomes. *Placenta* **105**, 85–93, <https://doi.org/10.1016/j.placenta.2021.01.020>
- 290 Ormazabal, V., Nair, S., Carrión, F., Mcintyre, H.D. and Salomon, C. (2022) The link between gestational diabetes and cardiovascular diseases: potential role of extracellular vesicles. *Cardiovasc. Diabetol.* **21**, 174, <https://doi.org/10.1186/s12933-022-01597-3>
- 291 Tryggstad, J.B., Vishwanath, A., Jiang, S., Mallappa, A., Teague, A.M., Takahashi, Y. et al. (2016) Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA. *Clin. Sci.* **130**, 1955–1967, <https://doi.org/10.1042/CS20160305>
- 292 Houshmand-Oeregaard, A., Schrölkamp, M., Kelstrup, L., Hansen, N.S., Hjort, L., Thuesen, A.C.B. et al. (2018) Increased expression of microRNA-15a and microRNA-15b in skeletal muscle from adult offspring of women with diabetes in pregnancy. *Hum. Mol. Genet.* **27**, 1763–1771, <https://doi.org/10.1093/hmg/ddy085>
- 293 Hromadnikova, I., Kotlabova, K., Dvorakova, L., Krofta, L. and Sirc, J. (2020) Substantially altered expression profile of diabetes/cardiovascular/cerebrovascular disease associated microRNAs in children descending from pregnancy complicated by gestational diabetes mellitus—one of several possible reasons for an increased cardiovascular risk. *Cells* **9**, 1557, <https://doi.org/10.3390/cells9061557>
- 294 Maloyan, A., Muralimanoharan, S., Huffman, S., Cox, L.A., Nathanielsz, P.W., Myatt, L. et al. (2013) Identification and comparative analyses of myocardial miRNAs involved in the fetal response to maternal obesity. *Physiol. Genomics* **45**, 889–900, <https://doi.org/10.1152/physiolgenomics.00050.2013>
- 295 He, L., Wang, X., Jin, Y., Xu, W., Guan, Y., Wu, J. et al. (2021) Identification and validation of the miRNA-mRNA regulatory network in fetoplacental arterial endothelial cells of gestational diabetes mellitus. *Bioengineered* **12**, 3503–3515, <https://doi.org/10.1080/21655979.2021.1950279>
- 296 Blackmore, H.L., Niu, Y., Fernandez-Twinn, D.S., Tarry-Adkins, J.L., Giussani, D.A. and Ozanne, S.E. (2014) Maternal diet-induced obesity programs cardiovascular dysfunction in adult male mouse offspring independent of current body weight. *Endocrinology* **155**, 3970–3980, <https://doi.org/10.1210/en.2014-1383>
- 297 Dearden, L., Bouret, S.G. and Ozanne, S.E. (2018) Sex and gender differences in developmental programming of metabolism. *Mol. Metab.* **15**, 8–19, <https://doi.org/10.1016/j.molmet.2018.04.007>
- 298 Beeson, J.H., Blackmore, H.L., Carr, S.K., Dearden, L., Duque-Guimarães, D.E., Kusinski, L.C. et al. (2018) Maternal exercise intervention in obese pregnancy improves the cardiovascular health of the adult male offspring. *Mol. Metab.* **16**, 35–44, <https://doi.org/10.1016/j.molmet.2018.06.009>
- 299 Loche, E., Blackmore, H.L., Carpenter, A.A., Beeson, J.H., Pinnock, A., Ashmore, T.J. et al. (2018) Maternal diet-induced obesity programmes cardiac dysfunction in male mice independently of post-weaning diet. *Cardiovasc. Res.* **114**, 1372–1384, <https://doi.org/10.1093/cvr/cvy082>
- 300 Nicholas, L.M., Nagao, M., Kusinski, L.C., Fernandez-Twinn, D.S., Eliasson, L. and Ozanne, S.E. (2020) Exposure to maternal obesity programs sex differences in pancreatic islets of the offspring in mice. *Diabetologia* **63**, 324–337, <https://doi.org/10.1007/s00125-019-05037-y>
- 301 Ferland-McCollough, D., Fernandez-Twinn, D.S., Cannell, I.G., David, H., Warner, M., Vaag, A.A. et al. (2012) Programming of adipose tissue miR-483-3p and GDF-3 expression by maternal diet in type 2 diabetes. *Cell Death Differ.* **19**, 1003–1012, <https://doi.org/10.1038/cdd.2011.183>
- 302 Fornes, D., White, V., Higa, R., Heinecke, F., Capobianco, E. and Jawerbaum, A. (2018) Sex-dependent changes in lipid metabolism, PPAR pathways and microRNAs that target PPARs in the fetal liver of rats with gestational diabetes. *Mol. Cell. Endocrinol.* **461**, 12–21, <https://doi.org/10.1016/j.mce.2017.08.004>
- 303 Joshi, A., Azuma, R., Akumuo, R., Goetzl, L. and Pinney, S.E. (2020) Gestational diabetes and maternal obesity are associated with sex-specific changes in miRNA and target gene expression in the fetus. *Int. J. Obes.* **44**, 1497–1507, <https://doi.org/10.1038/s41366-019-0485-y>
- 304 Shyamasundar, S., Ramya, S., Kandilya, D., Srinivasan, D.K., Bay, B.H., Ansari, S.A. et al. (2023) Maternal diabetes deregulates the expression of Mecp2 via miR-26b-5p in mouse embryonic neural stem cells. *Cells* **12**, 1516, <https://doi.org/10.3390/cells12111516>
- 305 Wang, F., Xu, C., Reece, E.A., Li, X., Wu, Y., Harman, C. et al. (2017) Protein kinase C- $\alpha$  suppresses autophagy and induces neural tube defects via miR-129-2 in diabetic pregnancy. *Nat. Commun.* **8**, 15182, <https://doi.org/10.1038/ncomms15182>
- 306 Frørup, C., Mirza, A.H., Yarani, R., Nielsen, L.B., Mathiesen, E.R., Damm, P. et al. (2021) Plasma exosome-enriched extracellular vesicles from lactating mothers with type 1 diabetes contain aberrant levels of miRNAs during the postpartum period. *Front Immunol.* **12**, <https://doi.org/10.3389/fimmu.2021.744509>
- 307 Fu, J. and Retnakaran, R. (2022) The life course perspective of gestational diabetes: An opportunity for the prevention of diabetes and heart disease in women. *EclinicalMed.* **45**, 101294, <https://doi.org/10.1016/j.eclinm.2022.101294>
- 308 Xiong, X., Saunders, L.D., Wang, F.L. and Demianczuk, N.N. (2001) Gestational diabetes mellitus: prevalence, risk factors, maternal and infant outcomes. *Int. J. Gynecol. Obstet.* **75**, 221–228, [https://doi.org/10.1016/S0020-7292\(01\)00496-9](https://doi.org/10.1016/S0020-7292(01)00496-9)
- 309 Rana, S., Lemoine, E., Granger, J.P. and Karumanchi, S.A. (2019) Preeclampsia: pathophysiology, challenges, and perspectives. *Circ. Res.* **124**, 1094–1112, <https://doi.org/10.1161/CIRCRESAHA.118.313276>
- 310 Zhang, C., Li, Q., Ren, N., Li, C., Wang, X., Xie, M. et al. (2015) Placental miR-106a~363 cluster is dysregulated in preeclamptic placenta. *Placenta* **36**, 250–252, <https://doi.org/10.1016/j.placenta.2014.11.020>
- 311 Hromadnikova, I., Kotlabova, K., Ondrackova, M., Kestlerova, A., Novotna, V., Hympanova, L. et al. (2013) Circulating C19MC microRNAs in preeclampsia, gestational hypertension, and fetal growth restriction. *Mediators Inflamm.* **2013**, 1–12, <https://doi.org/10.1155/2013/186041>
- 312 Laganà, A.S., Vitale, S.G., Sapia, F., Valenti, G., Corrado, F., Padula, F. et al. (2018) miRNA expression for early diagnosis of preeclampsia onset: hope or hype? *J. Maternal-Fetal Neonatal Med.* **31**, 817–821, <https://doi.org/10.1080/14767058.2017.1296426>
- 313 Joglekar, M.V., Wong, W.K.M., Ema, F.K., Georgiou, H.M., Shub, A., Hardikar, A.A. et al. (2021) Postpartum circulating microRNA enhances prediction of future type 2 diabetes in women with previous gestational diabetes. *Diabetologia* **64**, 1516–1526, <https://doi.org/10.1007/s00125-021-05429-z>
- 314 Lu, W. and Hu, C. (2022) Molecular biomarkers for gestational diabetes mellitus and postpartum diabetes. *Chin. Med. J. (Engl.)* **135**, 1940–1951, <https://doi.org/10.1097/CM9.0000000000002160>



- 315 Ares Blanco, J., Lambert, C., Fernandez-Sanjurjo, M., Morales-Sanchez, P., Pujante, P., Pinto-Hernández, P. et al. (2023) miR-24-3p and body mass index as Type 2 diabetes risk factors in Spanish women 15 years after gestational diabetes mellitus diagnosis. *Int. J. Mol. Sci.* **24**, 1152, <https://doi.org/10.3390/ijms24021152>
- 316 Valerio, J., Barabash, A., Garcia de la Torre, N., De Miguel, P., Melero, V., del Valle, L. et al. (2022) The relationship between serum adipokines, miR-222-3p, miR-103a-3p and glucose regulation in pregnancy and two to three years post-delivery in women with gestational diabetes mellitus adhering to mediterranean diet recommendations. *Nutrients* **14**, 4712, <https://doi.org/10.3390/nu14224712>
- 317 Kameswaran, V., Bramswig, N.C., McKenna, L.B., Penn, M., Schug, J., Hand, N.J. et al. (2014) Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. *Cell Metab.* **19**, 135–145, <https://doi.org/10.1016/j.cmet.2013.11.016>
- 318 Xiang, Y. (2015) miR-24 in diabetes. *Oncotarget* **6**, 16816–16817, <https://doi.org/10.18632/oncotarget.4795>
- 319 Bo, S., Valpreda, S., Menato, G., Bardelli, C., Botto, C., Gambino, R. et al. (2007) Should we consider gestational diabetes a vascular risk factor? *Atherosclerosis* **194**, e72–e79, <https://doi.org/10.1016/j.atherosclerosis.2006.09.017>
- 320 Thirunavukarasu, S., Ansari, F., Cubbon, R., Forbes, K., Bucciarelli-Ducci, C., Newby, D.E. et al. (2022) Maternal cardiac changes in women with obesity and gestational diabetes mellitus. *Diabetes Care.* **45**, 3007–3015, <https://doi.org/10.2337/dc22-0401>
- 321 Hromadnikova, I., Kotlabova, K. and Krofta, L. (2022) Cardiovascular disease-associated microRNAs as novel biomarkers of first-trimester screening for gestational diabetes mellitus in the absence of other pregnancy-related complications. *Int. J. Mol. Sci.* **23**, 10635, <https://doi.org/10.3390/ijms231810635>
- 322 Simmons, D., Immanuel, J., Hague, W.M., Teede, H., Nolan, C.J., Peek, M.J. et al. (2023) Treatment of gestational diabetes mellitus diagnosed early in pregnancy. *N. Engl. J. Med.* **388**, 2132–2144, <https://doi.org/10.1056/NEJMoa2214956>
- 323 Behboudi-Gandevani, S., Amiri, M., Bidhendi Yarandi, R. and Ramezani Tehrani, F. (2019) The impact of diagnostic criteria for gestational diabetes on its prevalence: a systematic review and meta-analysis. *Diabetol. Metab. Syndr.* **11**, 11, <https://doi.org/10.1186/s13098-019-0406-1>
- 324 Guarino, E., Delli Poggi, C., Grieco, G.E., Cenci, V., Ceccarelli, E., Crisci, I. et al. (2018) Circulating microRNAs as biomarkers of gestational diabetes mellitus: updates and perspectives. *Int. J. Endocrinol.* **2018**, 1–11, <https://doi.org/10.1155/2018/6380463>
- 325 Zhu, Y., Tian, F., Li, H., Zhou, Y., Lu, J. and Ge, Q. (2015) Profiling maternal plasma microRNA expression in early pregnancy to predict gestational diabetes mellitus. *Int. J. Gynecol. Obstet.* **130**, 49–53, <https://doi.org/10.1016/j.ijgo.2015.01.010>
- 326 Pinto-Hernández, P., Tomás-Zapico, C. and Iglesias-Gutiérrez, E. (2019) Circulating microRNAs as modifiable diagnostic biomarkers of gestational and transgenerational metabolic risk: can exercise play a role? *Noncoding RNA Investig.* **3**, 23–23, <https://doi.org/10.21037/ncri.2019.08.01>
- 327 Ye, F., Lu, X., van Neck, R., Jones, D.L. and Feng, Q. (2023) Novel circRNA-miRNA-mRNA networks regulated by maternal exercise in fetal hearts of pregestational diabetes. *Life Sci.* **314**, 121308, <https://doi.org/10.1016/j.lfs.2022.121308>
- 328 Stevanović-Silva, J., Beleza, J., Coxito, P., Rocha, H., Gaspar, T.B., Gärtner, F. et al. (2022) Exercise performed during pregnancy positively modulates liver metabolism and promotes mitochondrial biogenesis of female offspring in a rat model of diet-induced gestational diabetes. *Biochim. Biophys. Acta* **1868**, 166526, <https://doi.org/10.1016/j.bbadis.2022.166526>
- 329 Godoy, P.M., Barczak, A.J., DeHoff, P., Srinivasan, S., Etheridge, A., Galas, D. et al. (2019) Comparison of reproducibility, accuracy, sensitivity, and specificity of miRNA quantification platforms. *Cell Rep.* **29**, 4212.e5–4222.e5, <https://doi.org/10.1016/j.celrep.2019.11.078>
- 330 Bertoia, M.L., Bertrand, K.A., Sawyer, S.J., Rimm, E.B. and Mukamal, K.J. (2015) Reproducibility of circulating microRNAs in stored plasma samples. *PLoS ONE* **10**, e0136665, <https://doi.org/10.1371/journal.pone.0136665>
- 331 Mraz, M., Malinova, K., Mayer, J. and Pospisilova, S. (2009) MicroRNA isolation and stability in stored RNA samples. *Biochem. Biophys. Res. Commun.* **390**, 1–4, <https://doi.org/10.1016/j.bbrc.2009.09.061>